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Natural products have historically served as a major source for most of the therapeutically
relevant compounds. A significant fraction of these natural product-based drugs and leads are
derived from microorganisms. Although the traditional culture-based strategy has proven very
successful over the course of more than a century of investigation, it excludes a significant
portion of the molecules present in environmental samples because majority of the bacteria are
not readily amenable to culture-based strategies. This uncultured majority is believed to
represent 99% of bacterial species in the environment. Therefore, it has remained a significant
challenge to access the chemical diversity present in these microorganisms using culture-based
methods. Most modern natural product discovery efforts are faced with the hurdle of high
rediscovery rates (>99%) of known metabolites produced by easily cultured bacteria.

Metagenomics has evolved as an alternative approach to conventional microbial screening. By
directly cloning environmental DNA (eDNA or metagenome) in a surrogate host, one can
exhaustively investigate the metagenome, independent of the culturability of the source
organisms. Metagenomic approaches can thus provide access to previously untapped pools of

chemical diversity. These techniques have been employed in the current thesis to search for a
family of therapeutically relevant, polycyclic aromatic natural products, synthesized by Type II
polyketide synthases (PKSs) in soil-borne bacteria. Through the functional characterization of
soil eDNA-derived Type II PKS containing clones, herein we attempt to identify novel PKS
systems that encode structurally diverse metabolites and explore their biological activity
(Chapter 1).

My doctoral work towards the discovery of novel type II PKS derived natural products has led to
the elucidation of the mode of action of eDNA encoded antibiotics Fasamycins A and B. To
identify the target of the fasamycins, fasamycin A resistant mutants were generated. Nextgeneration sequencing of these mutants, along with in vitro biochemical assays, showed that
fasamycins inhibit the FabF gene of the type II fatty acid biosynthetic system. Subsequently,
candidate gene overexpression studies consolidated the mode of action of fasamycins. (Chapter
2)

Insights into the genomes of uncultured microorganisms indicate that they are rich in Type II
PKS gene clusters. In our attempt to identify novel aromatic polyketide natural products, we
investigated the eDNA of soil samples collected from Texas region for unique Type II PKSs
using homology-based metagenomic screening techniques. The eDNA-derived clones containing
unique type II polyketide synthase genes identified in this screening were examined for the
ability to produce clone-specific metabolites in Streptomyces. This led to the identification of
hitherto unknown biosynthetic gene cluster for Seitomycin, a Type II PKS derived antibiotic.
(Chapter 3)

In addition to the work using homology-based metagenomic techniques outlined above, three
unique Type II PKS clones were identified based on bioinformatics analysis and comparison
with previously characterized PKS gene clusters. These novel pathways were functionally
reconstructed from multiple overlapping clones using Transformation Associated Recombination
(TAR). Upon complete reassembly, all of the three PKS pathways were demonstrated to produce
clone-specific metabolites during heterologous expression studies in Streptomyces host. In future
studies, characterization of these metabolites is likely to lead to novel Type II PKS derived
natural products. (Chapter 4)
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CHAPTER 1
Introduction and Background

1.1 Natural Products
Throughout most of history, small molecule natural products have been a source of novel
therapeutics for a wide spectrum of diseases. Since the early 1800s, discovery of natural products
has started a new era of medicine where drugs could be purified from plants or microorganisms
and administered in precise dosage. The term natural product really means any naturally
occurring substance but is generally taken to mean a secondary metabolite - a molecule that has
no essential function in metabolism. It’s thought that these chemicals exist to increase the
likelihood of an organism’s survival by attracting or repelling other organisms. Among the first
reported examples of natural products were strychnine, morphine, atropine, quinine, and
colchicine. In 1826, E. Merck developed the first commercial natural product, morphine, and this
was followed by the first semisynthetic, pure drug based on a natural product, aspirin, by Bayer
in 1899.
The next milestone was the discovery of penicillin from the filamentous fungus Penicillium
notatum by Alexander Fleming in 1929. This truly ushered in the “Golden Age of Antibiotics”,
the time period from the 1940s to the 1970s. Pharmaceutical companies launched extensive
investigations of microbes as sources of novel antibiotics and led to the discovery of a host of
other antibacterial antibiotics, including the tetracyclines (e.g., doxycycline), cephalosporins,
aminoglycosides (e.g.,streptomycin), lipopeptides (e.g., daptomycin), glycopeptides (e.g.,
vancomycin), and macrocyclic compounds such as erythromycin. (Newman et al. 2000, Cragg
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and Newman 2001). Microbial natural products have also been the source of other anti-infective
drugs in the form of antibiotics having antifungal (e.g., amphotericin, nystatin) and antiparasitic
(e.g., ivermectin, fumagillin) activities. (Newman et al. 2000, Cragg and Newman 2001,
Newman and Cragg 2012). Microbes have provided the template for the development of
anticholesterolemic drugs, known as statins. The discovery of the fungal metabolites mevastatin
(compactin) and lovastatin as inhibitors of HMG-CoA reductase led to the development of
synthetic statin analogues, such as lovastatin and simvastatin (Mevacor). Antitumor antibiotics
such as anthracyclines (e.g., doxorubicin), enediynes (e.g., calicheamicin), ansamycins (e.g.,
geldanamycin), peptolides (e.g., dactinomycin), epothilones (e.g., ixabepilone), mitosanes (e.g.,
mitomycin C), etc. are all microbial natural products that continue to play significant role in the
drug discovery and development process. (Newman and Cragg 2012, Cragg et al. 2009, Cragg et
al. 2012). Rapamycins are another important class of immunosuppressive drugs that complement
the role of another microbial metabolite cyclosporine. (Cragg and Newman 2001). It is estimated
that almost 70% of the small molecule drugs have their origin in natural products. (Newman and
Cragg 2007). Thus, natural products have been, and continue to be, an indispensable source of
novel drugs and pharmaceutical leads for the treatment of many human diseases.
Natural products isolated from cultured organisms have provided a large proportion of the most
important pharmacophores discovered to date (Figure 1) (Newman, Cragg et al. 2003; Newman
and Cragg 2004; Newman and Cragg 2007). Their bioactivity is attributed, to a large extent, to
selective pressures that culminated in the evolution of structural and chemical properties of
natural products to function effectively in biological contexts. In the native microbial hosts, the
metabolites have been shown to play critical roles in processes like self-defense, nutrient
scavenging and virulence. (Omura, Ikeda et al. 2001; Wolfgang, Kulasekara et al. 2003;

2

Nougayrède, Homburg et al. 2006; Wyatt, Wang et al. 2010). Soil-dwelling bacteria, especially
actinomycetes, have been an abundant source of bioactive natural products. In fact, an estimated
two thirds of all clinically useful antibiotics come from one bacterial genus alone, Streptomyces
(Kieser et al. 2000). As a single gram of soil is predicted to harbor over 10,000 individual
bacterial species, soil-bacteria seem to represent a promising reservoir of novel natural products
with tremendous therapeutic potential (Torsvik et al. 1990; Curtis et al. 2002; Rappe and
Giovannoni 2003)
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Figure 1. Natural products as therapeutic agents

There are hundreds of thousands of different natural products reported in literature. The CRC
Dictionary of Natural Products (DNP) lists 190,939 records (DNP, Chapman and Hall, 2005).
There is no rigidly defined scheme for classifying natural products. Their immense diversity in
structure, function and biosynthesis is too vast to allow them to fit into a few simple categories.
However, widely accepted are five major classes of natural products: ployketide, non-ribosomal
peptides, alkaloids, terpenoids and enzyme co-factors.
1.1.1 Polyketides
Polyketides represent one of the largest families of secondary metabolites, especially abundant
among actenimycete bacteria, eukaryotic fungi and higher plants. They are a highly diverse
group of natural products having structurally intriguing carbon skeletons, which comprises
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polyphenols, macrolides, polyenes, enediynes and polyethers. Although their exact roles in
biological contexts are not known in all cases, it is believed that they function as pigments,
virulence factors, infochemicals, or for defense. From a pharmacological viewpoint, polyketides
are an important source of novel therapeutics. In particular, they are used in medicine mainly as
antibiotics, immunosuppressants, antiparasitics, cholesterol-lowering, and antitumor agents.
(O’Hagan 1991). Some notable examples include tetracyclines and erythromycin (antibiotics),
doxorubicin (anti-cancer), avermectin and monencin (antiparasitics), FK506 (immunosuppressant), all from the bacterial group that produces a large proportion of such compounds,
the actenomycetes.
These molecules are biologically synthesized by multifunctional polyketide synthases (PKSs),
which catalyze repeated decarboxylative condensations between acyl thioesters (usually acetyl,
propionyl, malonyl, or methylmalonyl) (Figure 2). Whereas the total chemical synthesis of
polyketides is highly challenging, it is remarkable that their vast structural and functional
diversity results from the controlled assembly of some of the simplest biosynthetic building
blocks. Since the first biosynthetic investigations by Collie, who also coined the term
‘polyketide’, and the acetogenin hypothesis by Barton (Staunton and Weissman 2001),
biosynthesis of polyketides has become a fertile area of research and discovery. With emerging
techniques in molecular biology (Hopwood 1997), it has now become possible to understand the
biosynthetic logic of polyketide diversity, and engineer biosynthetic pathways for the production
of novel drug candidates. (Wilkinson and Micklefield 2007, Weissman and Leadlay 2005).
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Figure 2. Polyketide biosynthesis: Concatenation of acetate units during polyketide biosynthesis,
the decarboxylation of malonyl-CoA (or methylmalonyl-CoA), generates a nucleophilic enolate
thioester which attacks an acyl thioester (or other starting unit) in a Claisen condensation

On the basis of architecture type and mode of action of the assembly lines, PKSs are classified in
various types (Figure 3). Type I refers to linearly arranged and covalently fused catalytic
domains within large multifunctional enzymes, where as the term type II indicates dissociable
complex of discrete and usually monofunctional enzymes. Furthermore, a third group of
multifunctional enzymes of the chalcone synthase type is denoted as type III PKSs (Figure 3).
Aside from the structures of the enzymes or enzyme complexes, the PKSs are also categorized as
iterative or non-iterative, that is, whether or not each KS domain catalyze more than one round of
elongation.
1.1.2. Type II polyketides
A number of polycyclic aromatic natural products are synthesized by polyketide synthases
(PKSs) in soil-borne bacteria. They exhibit anticancer (e.g. doxorubicin), antibacterial (e.g.
oxytetracycline), antifungal (e.g. pradimicin), antiviral (e.g. A-74528), antiparasitic (e.g.
frenolicin) and other related activities. These PKSs, also called type II PKSs because of their
relationship to type II fatty acid synthases from bacteria and plants, are a fascinating family of
multifunctional catalysts that synthesize a wide range of interesting and medicinally important
natural products.
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Iterative type II PKS systems are common in prokaryotic organisms. Methods for genetic
manipulation of Gram–positive actinomycetes, pioneered by D. A. Hopwood and coworkers,
(Malpartida and Hopwood 1984) provided the technical foundation for the cloning and
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sequencing of a number of aromatic polyketide biosynthetic gene clusters. For example, the
complete act gene cluster responsible for actinorhodin biosynthesis was cloned in 1984
(Malpartida and Hopwood 1984), and its PKS genes were fully sequenced by 1992 (FernandezMoreno, et al. 1992). A ketosynthase (KS), chain length factor (CLF) and acyl carrier protein
(ACP) are encoded within the act gene cluster; these subunits were designated the ‘minimal
PKS’ (Figure 3). Additional PKS subunits, including ketoreductases (KR), cyclases (CYC), and
aromatases (ARO) define the folding pattern of the nascent poly-beta keto intermediate. In
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almost all type II polyketide pathways, cyclases mediate polyketide cyclization to generate the
aromatic ring system (Figure 4). Studies indicate that the first cyclization (i.e. C9–C14 or C7–
C12) is regulated by the PKS and the presence or absence of a KR has some impact on the
preformation of a bend in the carbon chain. Cyclase functions are attributed to individual
cyclization steps, such as second and third ring formation, and so on. While cyclases catalyze
specific aldol condensations, aromatases support the cyclodehydration process (Hertweck 2009)
(Figure 4). Given the clinical and commercial success of a diverse collection of aromatic
compounds that arise from iterative type II polyketide synthases, considerable interest has
developed to gain access to these microbial secondary metabolites. Accessing this particular
class of polyketide natural products is the primary focus of the current doctoral work.
1.2. Metagenomics and uncultured microorganisms
Charting biologically relevant chemical space is of utmost importance for drug discovery and
development. However, the discovery of new natural product antibiotics has declined over the
past several decades (Fox 2006). There is more than one factor contributing to this decline. The
isolation of small molecules from bacteria or fungi from environmental sources mostly relies on
the decade-old methods and techniques (Figure 5). The traditional protocol used to isolate and
identify natural products from bacteria is to first culture an individual bacterium from the
environment, extract bacterial cultures using organic solvents, and isolate pure compounds
through activity-guided fractionations (Figure 5). However, the traditional culture-based
paradigm itself seems to be one of the major hurdles to new natural product discovery. Despite
decades of historical productivity, pharmaceutical companies have recently deemphasized
natural product discovery efforts due to the increasing rediscovery rates of common metabolites
produced by easily cultured bacteria - a rate that now exceeds 99%. (Newman et al. 2004,
8

Newman et al. 2007, Newman et al. 2012). The difficulties associated with culturing
environmental bacteria prevent traditional culture-dependent methods from being applied to a
significant fraction of the bacterial species found in nature. Microbial 16S rRNA sequencing
efforts indicate that only a small fraction of the world’s environmental microbes have been
cultured using standard microbiological methods. (Torsvik et al. 1990, Kaeberlein et al. 2002,
Zengler et al. 2002, Gans et al. 2005, Tringe et al. 2005). From the bacterial kingdom, this
minority is believed to represent less than 1% of all species in existence. These same analyses
also indicate that more than 80 major bacterial divisions exist, but only less than half are
represented by cultured isolates. (Schloss et al. 2004, Keller et al. 2004, DeSantis et al. 2006).
Such insights suggest that uncultured bacteria are likely the largest remaining pool of genetic and
chemical diversity on the planet. Thus, it is apparent that the vast majority of natural products
produced by microorganisms found in the biosphere are beyond the scope of the traditional
culture-dependent paradigm.
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Figure 5. Microbial natural product isolation: Traditional culture-based method. Cultured
environmental samples (in this example, bacteria) are isolated and crude extracts are generated.
Iterative rounds of fractionation and activity assays are used until a pure compound is obtained for
structural elucidation.

There are a number of different strategies, using both culture-dependent and culture-independent
9

methods, which are now being developed to access this untapped reservoir of chemical diversity.
Typically, culture-independent strategies involve direct cloning of the genetic material from an
environmental sample, which contains the genes encoding for small molecule (Figure 6). The
genetic diversity of all the bacteria in any given environmental sample has been termed the
“metagenome” (Handelsman, Rondon, Brady, et al. 1998). While genomics is the study of an
individual organism's DNA, metagenomics transcends the individual genome. Taking advantage
of the advances in DNA-sequencing technology, this new approach allows the study of entire
communities of microbes simultaneously, bypassing the need for isolation and culture. It
therefore seems likely that we can capture the biosynthetic potential of uncultured bacteria
through metagenomics and gain access to unidentified bioactive metabolites for future drug
discovery efforts. Metagenomics is fast evolving as an alternative to conventional microbial
screening for natural product discovery.
Studying natural product gene clusters using metagenomic techniques requires eDNA
(environmental DNA) cloning and sequence enrichment techniques. DNA extracted from
environmental sample, such as soil and water, contains large quantities of genetic material,
including secondary metabolite biosynthetic gene clusters (Figure 6). DNA extracted from
environmental sample, such as soil and water, contains large quantities of genetic material,
including secondary metabolite biosynthetic gene clusters. This eDNA is purified and cloned
into a vector that allows the high efficiency transformation of a tractable library host, typically E.
coli. To accomplish this, eDNA can be ligated into a cosmid vector, packaged into lambda phage
and transfected into E. coli (Brady 2007). This cloning method can captures up to 50 kb pieces of
eDNA in a single clone. Since the genes responsible for the biosynthesis of natural products are
typically clustered together, it is possible to capture an entire biosynthetic gene cluster or a large
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part of it on a single cosmid (Handelsman, Rondon, Brady et al. 1998).
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Figure 6. Metagenomic library construction and screening: eDNA is purified and cloned into a vector that
allows high efficiency transformation into a culturable library host. One of two primary screening
methodologies (functional/homology-based) are used to identify clone-specific molecules or biosynthetic
gene clusters for downstream heterologous expression and characterization efforts.

Metagenomic methods are universally applicable and have already been applied to microbial
communities from soils/sediments (Rondon et al. 2000; Brady et al. 2002; Voget et al. 2003),
rumen gut (Brulc et al. 2009), planktonic marine microbial assemblages (Beja et al. 2000,
Breitbart 2002), deep sea microbiota (Sogin et al. 2006), an acid mine site (Tyson et al. 2004),
arctic sediments and the Sargasso Sea (Venter et al. 2004). The foundation of all metagenomic
approaches is the isolation and subsequent examination of DNA extracted directly from naturally
occurring microbial populations, which avoids the difficulties associated with culturing
environmental bacteria (Handelsman et al. 1998). As previously mentioned, secondary
metabolite biosynthetic gene clusters are often clustered in the bacterial genome. Metagenomics
is particularly appealing to natural product researchers because of this characteristic clustering,
since most secondary metabolite biosynthetic gene clusters are under 100 kb, making it possible
to capture biosynthetic gene clusters on individual or, at most, a small number of overlapping
eDNA clones (Handelsman et al. 1998). Large scale cosmid cloning of environmental DNA
therefore provides a platform from which one can investigate secondary metabolite biosynthetic
gene clusters from uncultured bacteria.
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1.2.1. Functional metagenomic screening
One approach to access the chemical diversity of uncultured microbes is through expressiondependent or functional screening (Figure 6). In functional metagenomic studies, eDNA libraries
are examined in simple high throughput assays designed to identify clones that have phenotypes
traditionally associated with the production of small molecules, such as pigment production,
antibiosis, or altered colony morphology. One of the simplest strategies used to detect eDNA
clones that might produce small molecule antibiotics has been to screen libraries hosted in E. coli
for clones that generate zones of growth inhibition against test microbes in top agar overlay
assays. The isolation of clone specific metabolites produced by active eDNA clones identified
from bacterial top agar overlay assays has led to the characterization of a variety of new
longchain N-acylated amines (3), as well as a new isonitrile functionalized indole antibiotic (5)
(Figure 7) (Brady and Clardy 2000; Brady and Clardy 2005). Antibiotics have also been found
by examining pigmented eDNA clones, and also through the direct examination of fermentation
extracts from randomly selected clones (Wang, Graziani et al. 2000; Brady, Chao et al. 2001;
MacNeil, Tiong et al. 2001; Gillespie, Brady et al. 2002; Lim, Chung et al. 2005; Long, Dunlap
et al. 2005). Compounds with bioactivity identified from these types of studies include the
antibiotic pigments violacein (2) and indigo (1) all recovered from soil libraries (Figure 7).

Functional metagenomics has also been used to identify clones that produce proteins with
potential anti-infective properties (Schipper, Hornung et al. 2009). Although nearly all smallmolecule-focused functional metagenomic studies have been carried out in E. coli, it is likely
that the majority of the biosynthetic diversity present in an environmental sample is not
functionally accessible using the same heterologous host. A computational analysis of promoters
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and ribosomal binding sites used by a taxonomically diverse group of sequenced bacteria found
that at most, 40% of the enzymatic activities present within a typical metagenomic sample could
be accessed using E. coli as a heterologous host (Gabor, Alkema et al. 2004). Therefore, libraries
initially constructed in E. coli were later shuttled into different hosts including S. lividans,
Ralstonia metallodurans, Rhizobium leguminosraum, Agrobacterium tumefaciens, Burkholderia
graminis, Caulobacter vibrioides, and Pseudomonas

putida (Wang, Graziani et al. 2000;

Martinez, Kolvek et al. 2004; Li, Wexler et al. 2005; Craig, Chang et al. 2009; Craig, Chang et
al. 2010).
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Figure 7. Natural products identified through functional metagenomic screening

Functional metagenomic screening strategies have been used to identify eDNA clones carrying
natural product biosynthetic gene clusters. One primary advantage of a functional screen is that
no a priori knowledge of the biosynthetic enzymes is required to discover novel metabolites. In
functional screens, a secondary metabolite is directly linked to its biosynthetic genes allowing
the unbiased discovery of novel biosynthetic sequences that have not been characterized before.
Although several novel metabolites have been uncovered using functional screens, successful
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expression of entire biosynthetic gene clusters requires the coordinated production of multiple
proteins in a clone under laboratory culture conditions. Because the gene clusters isolated from a
metagenomic sample are of diverse phylogenetic origin, the likelihood that a gene cluster meets
all of these requirements is very low, and hit rates for functional screens of metagenomic
libraries are generally around 0.01% (Courtois, Cappellano et al. 2003; Williamson, Borlee et al.
2005; Guan, Ju et al. 2007; Brady, Simmons et al. 2009). Due to these limitations, functional
screens of metagenomic libraries have been designed so that they can be easily carried out on a
large number of clones.

Although functional metagenomic screening is a powerful technique to gain access to the
chemical diversity encoded in uncultured microorganisms, this strategy still requires some
optimization. As described earlier, metagenomic cloning relies primarily on cosmid-based
vectors. However, many canonical biosynthetic gene clusters are too large (>50 kb) to be
captured on single cosmids and are truncated. This technical hurdle presents a major limitation of
using functional assays to discover new natural products from cosmid-based eDNA libraries.
Aside from this, the diversity present in environmental microbiomes makes the selection of an
optimal heterologous screening host quite challenging (Torsvik, Øvreås et al. 2002).
Heterologous expression hosts are inherently limited in their capacity to functionally process
foreign DNA. The expanded use of phylogenetically diverse heterologous expression hosts will,
therefore, most likely continue to benefit functional screening efforts. Exploring vector-host
pairs that allow for the screening of metagenomic libraries in phylogenetically diverse
microorganisms have the potential to expand the chemical diversity accessed through functional
metagenomic studies.
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1.2.2. Homology based screening
Expression-independent or homology-based screening of metagenomes is based on PCR
amplification of conserved natural product biosynthetic gene sequences to identify and recover
gene clusters from environmental DNA (eDNA) libraries. This allows targeted recovery of
specific biosynthetic pathways from the genomes of all bacterial species present within an
environmental sample.
Homology-based screens rely on the homology of the unknown, eDNA-derived secondary
metabolite biosynthetic pathways to sequenced clusters of known metabolites. In these studies,
eDNA libraries are probed to identify clones that contain conserved sequences associated with
secondary metabolite biosynthesis. Bioinformatics analyses of sequences recovered through
homology screening allow for the exclusion of sequences that are likely associated with gene
clusters encoding for previously encountered metabolites, significantly reducing the likelihood
for redundant isolation and increasing the likelihood of finding hitherto rare metabolites. Thus,
homology-based screening coupled with phylogenetic analyses of sequences captured in large
eDNA libraries should permit routine discovery of biosynthetic gene clusters encoding for
metabolites belonging to even previously rare families of bioactive natural products.

Homology-based screening utilizes degenerate oligonucleotides to amplify sequence homologs
via the polymerase chain reaction (PCR) (Seow, Meurer et al. 1997). Degenerate PCR primers
are designed from previously sequenced conserved regions of a biosynthetic gene of interest.
Screening metagenomic libraries with these degenerate primers enables the identification and
recovery of individual clones with homologous genes from an eDNA library. These type of
screening can be used to find new derivatives of known metabolites by targeting pathway15

specific biosynthetic genes. These primers can also be designed to identify novel structures by
targeting conserved general biosynthetic genes found in a class of compounds. For example,
degenerate primers based on conserved regions of minimal PKS KSα gene are used to amplify
KSα sequences captured in the Texas eDNA library. The unique (<85% identity to previously
known KSα genes) eDNA-derived KSα sequences then used as probes to identify and recover the
cosmid clones containing type II PKS biosynthetic gene clusters from the metagenomic library
(Figure 8). There have been multiple reports in the literature describing the identification of
novel metabolites derived from type II PKS biosynthetic systems from eDNA samples
(Hertweck 2009).
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Figure 8. PCR-based screening for novel natural products (type II PKS): Degenerate PCR primers
designed to recognize a conserved region in KSα sequences from minPKS were used to amplify
partial KSα sequences from eDNA (Wawrik et al. 2005).

1.2.2.1. Novel metabolites
Homology-based metagenomic screening is proving to be a rewarding avenue to access the
structural diversity encoded by uncultured bacteria. It has been successfully used to find novel
structures by targeting conserved general biosynthetic genes found in a class of compounds. One
of the first groups of molecules targeted using this strategy was the iterative (type II, aromatic)
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polyketides. Type II polyketides utilize a small collection of biosynthetic enzymes to generate a
diverse array of scaffolds, which are modified by various downstream enzymes. Although the
gene clusters that encode the biosynthesis of these diverse metabolites can differ substantially in
gene content, they all encode a highly conserved minimal PKS composed of three proteins:
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Figure 9. Metabolites isolated in homology-based metagenomic screening. A number of aromatic polyketides have
been isolated from soil eDNA libraries.

ketosynthase alpha (KSα); ketosynthase beta/chain length factor (KSβ); and acyl carrier protein
(ACP). This “minimal PKS”, which is responsible for the iterative condensation of malonyl-CoA
into a nascent polyketide chain, possesses a conserved organization, and is therefore an ideal
target to identify using homology-based metagenomics (Macpherson et al. 1994). The
examination of eDNA libraries and metagenomic sequencing data for relatives of known
biosynthetic systems is likely to be a generally applicable strategy for identifying new structural
variants of many bacterially derived antibiotics, potentially providing ready access to compounds
with improved spectrum of activity (Figure 9). Kang and Brady recently identified a collection of
novel

bioactive

pentangular

polyphenols,

calixanthomycin

A,

arenimycins

C-D,

Arixanthomycins A-C (Kang and Brady 2014, Kang and Brady 2013) through homology-based
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screening. Using similar strategy, the antibiotic fasamycins (6) were isolated from soil and found
to inhibit FabF of type II fatty acid biosynthesis (Feng, Kallifidas et al. 2011; Feng, Chakraborty
et al. 2012). King et al. expressed a pathway encoding for the biosynthesis of a type II polyketide
and characterized a new molecule erdacin (8) (King et al 2009) with previously unknown
pentacyclic skeleton, lending credence to the idea that uncultured bacteria may contain chemical
diversity unlike that seen in cultured bacteria (King et al. 2009). A collection of fluostatins (7)
and the methicillin-resistant Staphylococcus aureus (MRSA)-active antibiotic tetarimycin A (9)
have also been isolated from soil libraries (Feng, Kim et al. 2010; Kallifidas, Kang et al. 2012)
(Figure 9). In addition to isolating type II polyketides, homology-based metagenomic screening
has been successfully used to identify novel tryptophan dimer analogues from eDNA libraries
(Chang et al. 2015, Chang and Brady 2014, Chang et al. 2013, Chang and Brady 2011).
1.2.2.2. Congeners of known metabolites
Homology-based metagenomic approaches have been used in a number of studies to identify
new derivatives of known compounds (Donia, Hathaway et al. 2006; Schmidt and Donia 2009;
Ziemert, Ishida et al. 2010). Banik et al. employed a PCR screen targeting OxyC, a glycopeptide
oxidative coupling enzyme, to identify a number of glycopeptide biosynthetic gene clusters from
soil eDNA libraries (Banik and Brady 2008; Banik, Craig et al. 2010) that produced novel mono,
di- and trisulfated glycopeptide congeners from the teicoplanin aglycone (11) (Figure 10) (Banik
and Brady 2008). In another homology-based metagenomic study, Kang et al. identified an
eDNA-derived cluster encoding for arimetamycin A (12), an anthracycline found to be more
potent than clinically used natural anthracyclines against multidrug-resistant cancer cells (Kang
and Brady 2013).
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Figure 10. Derivatives of known natural products identified in homology-based metagenomic screening: Three
eDNA-derived sulfotransferases were used to produce mono-, di- and trisulfated glycopeptide congeners from
teicoplanin aglycone. An antharcycline analogue with high activity against cancer cells was isolated in a similar
study.

1.3. Future of metagenomic mining
Recent development in a range of experimental techniques has made possible the identification,
isolation and cloning for novel biosynthetic genes at a reasonable pace. Metagenomics is one
such approach for engendering novel genes. The efforts described in this chapter clearly
demonstrate the potential of uncultured bacteria as a rich source of biologically active novel
small molecules and metagenomics as means for accessing such molecules from uncultured
microbes from essentially any environment. The foundation of all metagenomic approaches is
the isolation and subsequent examination of DNA extracted directly from naturally occurring
microbial populations, which avoids the difficulties associated with culturing environmental
bacteria. The contributions made by metagenomics to the already existing reservoir of
prokaryotic genes are quite impressive. However, metagenomics is still in its infancy in terms of
technical development. Advances in heterologous gene expression, library construction, vector
design and screening techniques will lead to further improvement towards a robust approach for
isolating natural products with expanded chemical space and unique biological activity. The
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results discussed in the current doctoral thesis begin to explore these areas in an endeavor to
discover novel microbial natural products.

20

CHAPTER 2

Target Identification of eDNA-Encoded Antibiotics Fasamycins A and B

2.1 Introduction
The potential clinical utility of any antibiotic can only be augmented by efforts to gain more
information about their mechanisms of action. A significant increase in bacterial resistance has
recently overcome almost every class of antimicrobials in clinical use (Levy and Marshall 2004).
Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus
(VRE) are two of the most widely spread antibiotic-resistant organisms that cause nosocomial
infections. Rates of resistance among these organisms have increased considerably in the past
decade. About 30% of Enterococcal and 70% of S. aureus infections are reported to be resistant
to common antibiotics (Moran et al. 2006, Klein et al. 2007). New antibiotics with novel targets
are needed to combat these common drug resistant phenotypes. Discovery of novel antibiotics
and elucidation of their molecular targets is therefore key to success in our battle against multidrug resistant microorganisms.
One approach for determining the mode of action of a small molecule involves the selection and
full genome sequencing of mutants that acquire compound resistance (O’Neill and Chopra
2004). The current chapter describes our efforts to decipher the mode of action of the novel Type
II PKS derived antibiotics Fasamycins A (1) and B (2) employing this strategy (Figure 11).
These two antibiotics were initially identified in a metagenomic homology-based screening
endeavor through heterologous expression of Type II (iterative, aromatic) polyketide (PK)
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biosynthetic gene clusters cloned directly from soil samples. These metabolites show activity
against methicillin-resistant S. aureus and vancomycin-resistant E. faecalis (Feng, Kallifidas et
al. 2011) (Figure 11).

Fasamycins bear close structural resemblance to KB-3346-5 substances reported in patent
literature (Satoshi et al. 2009). However, there is no report on the mode of action of the
fasamycins or that of the KB-3346-5 substances. In the current study, we generated multiple
fasamycin mutant strains and sequenced their genomes. Each strain contained mutations in the
FabT gene of Type II fatty acid synthase (FASII) cluster. FabT is a transcriptional repressor that
regulates expression of FASII genes in E. faecalis. Disruption of FabT is predicted to augment
the expression of this gene cluster. We therefore employed the constitutive overexpression
strategy to find out which gene from the FASII is responsible for the antibiotic activity of the
fasamycins. Subsequent in vitro biochemical assays confirmed the identification FabF as the in
vivo target of the fasamycins.
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Figure 11. Antibiotics Fasamycins A (1) and B (2) were identified through the
heterologous expression of type II polyketide gene cluster cloned directly from soil
samples. Fasamycins showed activity against methicillin-resistant Staphylococcus aureus
and vancomycinresistant Enterococcus faecalis (Feng, Kallifidas et al. 2011)

2.2 Results
Fasamycins A and B are environmental DNA (eDNA) derived antibiotics from a Type II PKS

22

biosynthetic gene cluster (Feng, Kallifidas et al. 2011). Both metabolites demonstrate Grampositive specific antibiotic activity (Table 1).
Table 1. Biological Activity of Fasamycins A (1) and B (2)
1a

2

Bacillus subtilus BR151

3.1

6.25

Staphylococcus aureus 6538P

3.1

6.25

Staphylococcus aureus USA300 (MRSA)

3.1

6.25

Enterococcus faecalis OG1RF

0.8

6.25

Enterococcus faecalis EF16 (VRA)

0.8

6.25

Escherichia coli EC100

>100

>100

Escherichia coli BAS849

12.5
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Ralstonia metallidurans CH34

>100

>100

Burkholderia thailandensis E264

>100

>100

Eukaryote
Saccharomyces cerevisiae w303

>100

>100

Organism
Gram-positive bacteria

Gram-negative bacteria

aMinimum

inhibitory concentrations are reported as µg/mL.

Monohalogenated Fasamycin A consistently showed higher activity than its dihalogenated
counterpart, Fasamycin B against the Gram-positive bacteria that were examined (Table 1).
Although the fasamycins are inactive against wild-type Gram-negative bacteria, they still exhibit
activity against membrane permeabilized E. coli (BAS849). This data suggests that the lack of
antibiotic activity of fasamycins towards Gram-negative bacteria is most likely due to their
inability to access the right target. Neither metabolite showed cytotoxicity against yeast even at
the highest concentrations tested.

Investigation of antibiotic resistance strains can provide useful insights into the mode of action of
the particular antibiotic. To decipher the mechanistic principles of the fasamycins, a resistance
23

phenotype selection strategy was employed. A single wild-type colony of E. faecalis OG1RF
was grown to confluence overnight and the resulting culture was plated on LB agar containing
about 6 times the Minimum Inhibitory Concentration (MIC) for Fasamycin A (5 µg/mL)
(Bourgogne et al. 2008, Dunny et al. 1978). For every 108−109 bacterial cells we plated, one
grew at this elevated Fasamycin A concentration. The advantage of this is that by selecting
mutants from a natural population of cells instead of from cultures treated with mutagenizing
agents, the number of mutations per genome is minimized. With only a small number of
mutations per genome, it should be much easier to establish a functional link between a
resistance phenotype and the specific mutation leading to this phenotype.

Genomic DNA isolated from nine unique resistant colonies was sequenced using Illumina
HiSeq2000 technology. The mutant genomes were then compared to E. faecalis OG1RF genome
and queried for sequence differences (Figure 12). In all cases, the mutations were found in the
fabT gene of the fasamycin resistant mutant strains. In total, nine mutant strains were sequenced
and five unique fabT mutations (M1−M5) were found, each of which is predicted to result in
truncation of the fabT gene product (Figure 13).

These mutations were further confirmed by PCR amplification and re-sequencing of the fabT
locus from each mutant. The fabT gene is predicted to encode a MarR-like transcriptional
repressor (Seoane and Levy 1995, Lu et al. 2004). In E. faecalis, fabT is found in the type II
fatty acid biosynthesis (FASII) gene cluster (Figure 13) (Schujman and Mendoza, 2008).
Therefore, if the FabT transcriptional repressor is unable to express functional protein product, it
will to lead to an increased expression of this fatty acid biosynthesis gene cluster. Based on this
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Figure 12. Alignment of fabT mutations with reference genome sequence. Sequencing reads were aligned to the E.
faecalis OG1RF genome assembly from Baylor University using the Stampy alignment package. Consensus fabT
gene sequences (M1-M5) observed in fasamycin resistant mutants are shown. Mutations and stop codons are
highlighted in red. (Adapted from Feng, Chakaraborty et al. 2012)
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observation, we hypothesized that if the primary in vivo antibacterial target of the fasamycins is a
FASII biosynthetic enzyme, constitutive overexpression of the FASII gene cluster could lead to
an increased MIC for Fasamycin A.

Figure 13. Genomic DNA from nine unique resistant strains were isolated and sequenced. Nine sequenced mutant strains
contained five different mutations. All mutations were in the fabT gene and are predicted to result in truncated gene
product. FabT is a transcriptional repressor that regulates the expression of the FASII gene cluster in E. faecalis. The five
unique fabT mutations (M1−M5) that we observed are shown. (Adapted from Feng, Chakraborty et al. 2012)

To test our hypothesis, the fasamycins were tested in an in vitro fatty acid elongation assay. This
assay employed crude FASII extract that contains all of the enzymes required for fatty acid
elongation, long-chain acyl CoA (lauroyl-CoA) starter units, and [14C]-malonyl CoA that
together are used to extend fatty acids on purified holo-ACP substrates. ACP-linked long-chain
fatty acids are then captured using a phospholipid Flashplate, and

14

C incorporation into newly

generated fatty acids is read by a scintillation counter. In elongation assays with S. aureus FASII
extract and recombinant S. aureus 6-His-ACP (6 His-SA-ACP), Fasamycins A and B both
inhibit fatty acid elongation (IC50 = 50 and 80 µg/mL, respectively) and show inhibition curves
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similar to those of other known FASII inhibitors, BABX and Cerulinn (Figure 14).

Figure 14. Activity of the Fasamycins A and B was tested in an in vitro fatty acid elongation assay. Crude FASII
extract from S. aureus and recombinant S. aureus 6-His-ACP (6-His-SA-ACP) were used. Both Fasamycins A and
B inhibit fatty acid elongation (IC50 = 50 and 80 µg/mL, respectively) and show inhibition curves similar to those of
other known FASII inhibitors. Reactions were run with an excess of [14C]-malonyl-CoA and lauroyl-CoA.
Elongation assays were run in duplicate. (Adapted from Feng, Chakraborty et al. 2012)

Based on their ability to inhibit FASII elongation pathway in in vitro assay, only five FASII
enzymes, FabD, F, G, K, and Z, could potentially be candidates for fasamycins’ targets (Figure
15).
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Figure 15. Schematic of FASII biosynthesis. Based on the data obtained from the in vitro FASII elongation assay,
only five FASII enzymes, FabD, F, G, K, and Z, appear to be potential candidates as fasamycins’ target.

To distinguish the inhibition of FabD or FabF from the reductive enzymes of the elongation
cycle (FabG, Z, and K), FASII elongation assays were subjected to urea polyacrylamide gel
electrophoresis. With urea gels it is possible to resolve malonyl-ACP, the product of FabD, from
the longer chain acyl-ACPs generated in the FASII elongation cycle. It is apparent in Figure 16
that Fasamycin A does not inhibit FabD-dependent formation of malonyl-ACP (Figure 16, upper
band) but does inhibit the formation of long-chain acyl-ACPs from the FabD product (Figure 16,
lower bands).
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Figure 16. In vitro fatty acid elongation assays use a long-chain acyl CoA starter and the incorporation of [14C]malonyl-CoA to measure FASII activity. The reactions were run using lauroyl-CoA, recombinant 6His-SA-ACP,
and crude S. aureus FASII extracts. Fasamycin A inhibits fatty acid elongation but does not inhibit FabD-dependent
formation of malonyl-ACP. Reactions were run on a 16% polyacrylamide gel containing 4 M urea to resolve 14Clabeled malonyl-ACP (upper band) from 14C-labeled long-chain ACPs (lower bands). Lane 1, control reaction
without lauroyl-CoA; lane 2, complete reaction; lane 3, 200 µg/mL fasamycin A; lane 4, 200 µg/mL BABX.
(Adapted from Feng, Chakraborty et al. 2012)

The absence of any labeled long-chain acyl-ACPs in the Fasamycin A-containing reaction
indicates that Fasamycin A inhibits FabF, the initial condensation step of the elongation cycle,
and not simply a reductive step (FabG, K, and Z) in this cycle. FabF is one of two FASII-specific
condensation enzymes. It is specifically used in the fatty acid chain elongation cycle, while the
second condensing enzyme, FabH, is used in fatty acid initiation (Figure 15). Our biochemical
studies do not rule out the possibility that the fasamycins might also inhibit FabH.

Both gene knockdown and overexpression strategies have been used to identify the protein
targets of other FASII inhibitors (Wang et al. 2007). For this study, candidate gene
overexpression was used to further confirm the specific target of fasamycins. In this strategy,
each FASII gene was individually cloned, overexpressed and assayed for the ability to confer
Fasamycin A resistance to E. faecalis. FASII genes were PCR-amplified from wild-type E.
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faecalis genomic DNA and cloned into the E. coli−E. faecalis shuttle expression vector,
pMGS100 (Fujimoto and Ike, 2001). Individual FASII gene expression constructs were then
checked for the ability to confer Fasamycin A tolerance to wild-type E. faecalis. As would be
expected for a FabF specific antibiotic, only E. faecalis transformed with the FabF
overexpression construct grew robustly in the presence of lethal concentrations of Fasamycin A
(Figure 17a).
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Figure 17. a) Candidate gene over expression assay. Individual FASII gene expression constructs were examined
for the ability to confer Fasamycin A tolerance to wild-type E. faecalis. Only E. faecalis transformed with the FabF
overexpression construct grew robustly in the presence of lethal concentrations of Fasamycin A. A FabT knockout
mutant with the M1 mutation and wild-type E. faecalis transformed with either a vector control or individual FASII
overexpression constructs were inoculated onto LB agar containing 5 µg/mL Fasamycin A. b) The MIC ratios for
antibiotics measured against wild-type E. faecalis and E. faecalis transformed with either the fabF or fabH
overexpression constructs are listed. (Adapted from Feng, Chakraborty et al. 2012)

To further corroborate our results, we used Cerulenin, a well-characterized FabF inhibitor as a
control. Cerulenin showed a similar MIC profile against these same FASII overexpression
strains, while antibiotics with different protein targets did not exhibit elevated MICs against
FASII overexpression strains (Figure 17b).
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18). BABX is a know FabF inhibitor (Kodali et al. 2005, Herath et al. 2005). BABX and
Fasamycin A also show very similar in vitro FASII and FabF inhibitory activities (Figures 14
and 16). As with Fasamycin A, BABX shows reduced activity against the FabF overexpression
strain but not against any other FASII gene overexpression strains (Figure 17b).

2.3 Discussion

In most bacteria, fatty acid biosynthesis is catalyzed by a group of highly conserved proteins
known as Fatty acid synthesis type II (FASII) system enzymes. FASII system enzymes are
essential for bacterial membrane lipid biosynthesis and represent increasingly promising targets
for the discovery of antibacterial agents with new mechanisms of action (Zhang et al. 2006,
Wright and Reynolds 2007). Compounds that target the bacterial FAS pathway are not toxic
against humans because of radical differences in bacterial and human protein structures.
Additionally, FAS is vital to cell physiology and aids in the design of highly effective genusspecific inhibitors against major pathogens (Parsons and Rock 2011). Therefore, FAS systems
are one of the most attractive biochemical pathways to be used as targets for new antibacterial
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agents. So far, there have been only a handful of reports regarding FASII inhibitors as
therapeutic agents. Only two FASII inhibitors, Triclosan and Isoniazid, both of which target the
enoyl-acyl carrier protein reductase FabI, are used commercially as antibiotics. FabF-specific
antibiotics like the fasamycins show activity against therapeutically relevant antibiotic resistant
bacteria. In the case of the fasamycins and BABX, the high convergence to the same
pharmacophore on at least two separate occasions, suggests this may provide a promising lead
scaffold for future drug development against resistant strains. Optimizing the chloro-gemdimethyl-anthracenone pharmacophore and the variable region could yield additional FabFspecific antibiotics with increased efficacy and potentially differing spectra of activity. In fact,
the specific chlorination pattern on the gem–dimethylanthracenone substructure is clearly
important for the fasamycins’ activity against E. faecalis, as the monohalogenated analogue 1 is
almost an order of magnitude more active against this pathogen than the dihalogenated derivative
2. The study presented in this chapter leads us to believe that we need to expand upon both
available and yet unknown scaffolds to identify new FASII inhibitors that may have antibacterial
potential against resistant bacterial strains.
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2.4 Materials and Methods

2.4.1. Isolation of Fasamycins A (1) and B (2)
Streptomyces albus transformed with the eDNA-derived cosmid cosAZ154 was grown in ISP4
medium containing 5% HP-20 resin at 30 °C (200 rpm) for 15 days. The HP-20 resin was
collected, washed with water, and then soaked with methanol. The methanol eluent was
fractionated on a silica gel flash-column using a CHCl3:MeOH (0.1% acetic acid) step gradient.
Compounds 1 and 2 eluted from this column with the 95:5 CHCl3:MeOH fraction. Each
compound was then purified by reversed-phase (XBridge C18, 10 X 150 mm, 5 µm) HPLC (7
mL/ min) using a linear gradient from 10:90 H2O:MeOH (containing 0.1% formic acid) to 100%
MeOH (containing 0.1% formic acid) over 30 min. Fasamycins A and B are produced at
approximately 0.5 mg/L (Feng, Kallifidas et al. 2011). BABX was purchased from Santa Cruz
Biotechnology.

2.4.2. Selection of Enterococcus faecalis strains resistant to Fasamycin A
E. faecalis OG1RF was grown overnight in Lysogeny Broth (LB) (Bertani 2004) at 37 °C, and
100 µL of the overnight culture was spread on a LB agar plate containing 5 µg/mL Fasamycin A.
The plate was incubated at 37 °C. Resistant colonies appeared after 18 h. Nine resistant colonies
were picked and struck on selection plates, and then cultures of the mutants grown in the absence
of fasamycin were used for sequencing. Selection and analysis of resistant mutants were
performed by Dr. Z. Feng.
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2.4.3. Genome sequencing and analysis methods
Library Preparation. Genomic DNA libraries were prepared using Illumina TruSeq library kits
in accordance with the manufacturer’s protocols. Briefly, genomic DNA was sheared using a
Covaris S2 ultrasonicator, the resultant dsDNA fragments were end-repaired and A-tailed, and
indexed adapters were ligated to the end-repaired DNA. PCR was performed for 10 cycles, and
the libraries were quantitated using an Agilent Bioanalyzer 2100 and a High-Sensitivity DNA
kit. Indexed adapters were used to allow for the multiplexing of samples at the sequencing stage.

Sequencing and Raw Data Analysis. Samples were sequenced on an Illumina HiSeq2000 for 101
cycles, with an additional 7 cycles for the indexing read. Sequencing was performed according to
manufacturer’s protocols using TruSeq chemistry. Image data were analyzed in real time by the
onboard RTA software package. Bcl files produced by RTA were converted to qseq files by
Illumina’s OLB1 (Satoshi et al. 2009). Software package, and the qseq files were then converted
to a fastq file for subsequent analysis.

Alignments and Variant Detection. Sequencing reads were aligned to the E. faecalis OG1RF
genome assembly from Baylor University using the Stampy alignment package. The BWA
aligner within Stampy was used to decrease processing time (Bourgogne et al. 2008, Albers et al.
2011). BWA and Stampy allow for gapped alignment to facilitate the alignment of sequencing
reads in situations where there is significant heterogeneity due to sequence insertions, deletions,
or other lesions with regard to the reference genome. The alignment files were processed by
Dindel and the Samtools mpileup program to yield potential variant calls consisting of single
nucleotide polymorphisms, insertions, and deletions (Lunter and Goodson, 2011, Li et al. 2009).
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Confirmation of fabT Mutations. Sanger sequencing of fabT genes PCR amplified from resistant
strains was used to verify each fabT mutation detected in the Illumina sequencing experiment
(Supporting Information). Colony PCR was performed using whole cells, fabT flanking primers
(fabTF

TGCTTATTTACGATATAGTTTGTGCTTATTTACGATATAGTTTG,

fabTR

TGAAGATTTTTTAGTGCTC), Phusion High-Fidelity DNA polymerase (New England
Biolabs), and the following cycling parameters: denaturation (98 °C, 2 min), 10 touchdown
cycles (98 °C, 20 s; 55 °C (dt −1 °C/cycle), 30 s; 72 °C, 30 s), 30 standard cycles (98 °C, 20 s;
45 °C, 30 s; 72 °C, 30 s), and a final extension step (72 °C, 7 min). Gel-purified amplicons were
sequenced from both ends using the PCR primers.

2.4.4. Cloning FASII genes from E. faecalis OG1RF
Each individual gene in the FASII gene cluster of E. faecalis was amplified by PCR using E.
faecalis OG1RF genomic DNA as a template and Phusion High-Fidelity DNA polymerase. The
primers used are listed in Table 2. PCR amplicons of the correct size were double-digested with
EagI (or NotI) and NruI (or ScaI) and ligated with the pMGS100 E. faecalis expression vector
that had also been double-digested with EagI and NruI (Fujimoto and Ike 2001). Each of the
constructs was transferred into E. faecalis by electroporation transformation (Fujimoto, et al.,
1991).

2.4.5. Bioactivity: Growth on elevated concentrations of Fasamycin A
Each E. faecalis strains harboring individual FASII biosynthetic gene expression construct was
grown overnight at 37 °C in LB containing 12.5 µg/ mL of chloramphenicol. Overnight cultures
were diluted 104-fold and 5 µL aliquots of each diluted culture were then inoculated onto a LB

35

agar plate containing 12.5 µg/mL of chloramphenicol and 5 µg/mL of fasamycin A. Plates were
incubated at 37 °C for 18 h, and examined for spots of growth or no growth. Wild-type E.
faecalis OG1RF transformed with the empty pMGS100 expression vector was used as a negative
control. Positive control was a strain containing the M1 mutation, transformed with the empty
pMGS100 expression vector.

2.4.6. Bioactivity: Ex vivo studies
In these studies, E. faecalis strains harboring FASII gene expression constructs were examined
for resistance to Fasamycin A as well as other antibiotics. Wild-type E. faecalis transformed with
empty pMGS100 was used as control. Overnight cultures grown in LB with 12.5 µg/mL
chloramphenicol were diluted 106-fold. 50 µL aliquot of the dilute cultures were added to each
well of a 96-well microtiter plate. Fasamycin A and other compounds were dissolved in
methanol at 5 mg/mL concentration and diluted 100-fold with LB medium. 150 µL of this
solution was added to the first well of the microtiter plate and then serially diluted across the
plate. The plates were incubated at 30 °C for 24−48 h. The lowest concentration at which no
bacterial growth was observed after 24 h are reported as minimum inhibitory concentrations
(MICs). MICs against other microorganisms were determined in the same manner. Yeast extract
-peptone-dextrose (YPD) broth was used as media to conduct MIC studies for yeast.
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Table 2. Primers Used for Cloning E. faecalis FASII Genes
Name

Sequencea

FabH_For

GCGCCGGCCGATGAAGAATTATGCACGAATT

FabH_Rev

GCGCAGTACTTTTTACAGCGTTAGGAGCAG

acpP_For

GCGCCGGCCGATGGTATTTGAAAAAATTCAA

acpP_Rev

GCGCTCGCGACAGCCCCCTATTTTCATGTAT

FabK_For

GCGCCGGCCGATGAAGTGTACTTATCTTAGA

FabK_Rev

GCGCTCGCGATCACTTAGCCCCAACGCTGAT

FabD_For

GCGCCGGCCGATGAGGTGTCGTATGAAAACA

FabD_Rev

GCGCTCGCGACCATTTTTTACCTCCCAGTAAG

FabG_For

GCGCCGGCCGATGGAATTAACAGGGAAAAACG

FabG_Rev

GCGCTCGCGACCTTTCGTTTATCCGTGCATG

FabF_For

GCGCCGGCCGATGAATCGAGTAGTTATTACCGG

FabF_Rev

GCGCTCGCGAACTGCATGTTAATCCTCCCAG

accB_For

GCGCCGGCCGATGCAGTTAGAAGAAGTAAAAGC

accB_Rev

GCGCTCGCGAGTTAATTTCATGTTTTATTCTCC

FabZ_For

GCGCCGGCCGATGAAATTAACAATTACAGAAATTC

FabZ_Rev

GCGCAGTACTCGAAAACATTTTTCACCTATCC

accC_For

GCGCGCGGCCGCATGTTTTCGAAAGTATTAATCGC

accC_Rev

GCGCAGTACTCTTGCGGCGTTCTTTCTTTAATG

accD_For

GCGCGCGGCCGCATGGCATTATTTAAAAAGAAA

accD_Rev

GCGCTCGCGATTAGCGCCACCCTTCCAA

accA_For

GCGCCGGCCGATGGAAAAGAAAACAGCCAATGA

accA_Rev

GCGCTCGCGAGAGTAGTAACTTCTAATATTTGCG

aRestriction

sites added to each primer are underlined.

2.4.7. Bioactivity: In Vitro studies
Acyl Carrier Protein (ACP) Cloning. In order to clone Acyl Carrier Protein (ACP), the ACP
gene from S. aureus was amplified from S. aureus genomic DNA using the following primers
and

PCR

conditions.

Primers:

GCGCGGATCCGATGGAAAATTTCGATAAAGTAA;

forward
reverse

StaphACPFHis,
StaphACPR,

GCGCAAGCTTATTTTTCAAGACTGTTAATA (restriction sites added for cloning are shown
37

in bold). Cycling parameters: denaturation (98 °C, 2 min), 35 cycles (98 °C, 20 s; 55 °C, 30 s; 72
°C, 30 s), and a final extension step (72 °C, 7 min). 50 µL reaction conditions: 10 µL of 5X
Phusion HF buffer, 1.5 µL of DMSO, 0.3 µL of each 100 mM oligonucleotide primer, 1 µL of 10
mM dNTPs mix, 1 unit of Phusion High-Fidelity DNA polymerase and water as needed.
Amplicons were doubly digested with BamHI/HindIII, ligated into BamHI/HindIII digested
pColaDuet-1 (Novagen), and then transformed into E. coli BAP1 cells to yield pColaDuet: 6HisSA-ACP. BAP1 is a BL21(DE3)-derived expression strain that contains an inducible
phosphopantethienyl transferase (sfp gene), which should assist with generating the desired holoACP (Pfeifer, et al., 2001). Cloning was performed by Dr. Z. Zheng.

Expression and Purification of 6His-SA-ACP. 1 L LB media was inoculated with overnight
culture of BAP1/pColaDuet:6His-SA-ACP (1:1000 dilution). It was then grown at 37 °C to an
OD600 of 0.6. The incubation temperature was then reduced to 20 °C, and after 1 h, IPTG (0.5
mM) was added to induce protein expression. After an additional 16 h at 20 °C, the cells were
collected by centrifugation (3200g, 15 min). The cell-pellet was resuspended in 40 mL of lysis
buffer (50 mM Tris, pH 7.5, 0.3 M NaCl, 10 mM imidazole), and the cells were lysed by
sonication. Crude cell lysates were centrifuged at 25000g for 30 min and the supernatant was
incubated at 4 °C for 15 min with 1 mL of Ni-NTA resin (Qiagen). This mixture was washed
with 20 mL of lysis buffer and then 20 mL of lysis buffer containing 50 mM imidazole. 6HisSA-ACP was subsequently eluted with 5 mL of lysis buffer containing 125 mM imidazole. 6HisSA-ACP was further purified by anion-exchange chromatography (Mono Q 10/100 GL) using a
linear gradient from 0.1 M NaCl (10 mM Tris, pH 7.5) to 1 M NaCl (10 mM Tris, pH 7.5) over
120 min. Protein concentrations were determined with the Bradford assay. Aliquots of protein
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were flash-frozen in liquid nitrogen and stored at −80 °C.

FASII Enzyme Extract from S. aureus. For the preparation of FASII enzymes (Kodali et al.,
2005) 6 L of S. aureus was grown in LB media at 37 °C until to stationary phase is reached.
Cells were then harvested by centrifugation (2500g, 10 min, 4 °C) and the cell pellet washed
twice with ice-cold FASII buffer (0.1 M sodium phosphate, pH 7, 1 mM EDTA, 5 mM βmercaptoethanol). The pellet resuspended in 0.5 L of the same buffer and lysed using a French
press. Cell debris was separated by centrifugation (20000 rpm, 15 min, 4 °C) and the supernatant
was collected. In order to precipitate the protein, ammonium sulfate was slowly added to the
supernatant to reach 45% saturation. Precipitated protein was removed by centrifugation (10000
rpm, 5 min, 4 °C), and ammonium sulfate was slowly added to the supernatant to reach 80%
saturation. Precipitated protein was collected by centrifugation (10000 rpm, 5 min, 4 °C). The
resulting pellet was resuspended in 20 mL of FASII buffer and dialyzed (10 kDa MW cutoff) at
4 °C. Buffer was changed four times during the process. This crude extract from S. aureus
should contain all the factors necessary for reconstituting the FASII elongation process in vitro.
Protein concentration measurements were done using the Bradford assay. Aliquots of protein
were stored at −80 °C after flash freezing in liquid nitrogen.

FASII Elongation Assay. 96-well phospholipid Flashplates (Perkin-Elmer) were used to perform
FASII inhibition assays (Kodali et al., 2005). The buffer used in this assay was composed of 100
mM sodium phosphate (pH 7), 5 mM EDTA, 1 mM NADPH, 1 mM NADH, 150 µm DTT, 5
mM β-mercaptoethanol, 20 µM lauroyl-CoA, 4% Me2SO, and 5 µM DTT pretreated 6xHis-SAACP. 0.4 µg of the FASII protein extract was added to 40 µL of this buffer and incubated with
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inhibitor at room temperature for 20 min. Elongation reactions were initiated with the addition of
8 µL of C-2 labeled [14C]-malonyl-CoA (Perkin-Elmer 57.5 mCi/mmol) dissolved in water to a
final concentration of 4 µM. After 60 min at 37 °C, reactions were quenched by adding 80 µL of
14% perchloric acid. The 96-well phospholipid Flashplates were then sealed and incubated at
room temperature overnight. The reactions were assessed using a TopCount scintillation counter
(Trilux Microbeta).

FASII Elongation and ACP Loading Assay. For this assay, 0.2 µg of FASII extract was added to
50 µL of the buffer mentioned above and reactions were run in microcentrifuge tubes. After a
preincubation with inhibitor at room temperature for 20 min, fatty acid elongation was initiated
by adding a 10 µL aliquot of C-2 labeled [14C]-malonyl-CoA (Perkin-Elmer 57.5 mCi/mmol,
final concentration 4 µM). After 30 min of incubation at 37 °C, 15 µL of native sample buffer
was added to each reaction. 16% polyacrylamide gels containing 4 M urea were used to resolve
the reaction mixtures. Gels were blotted on to polyvinylidene difluoride membranes (Bio-Rad)
and imaged using a PhosphorImager.
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CHAPTER 3

Homology-Based Metagenomic Screening Efforts towards the Identification of
Novel Type II Polyketide Synthase Gene Clusters
3.1 Introduction
Given the clinical and commercial success of a diverse collection of aromatic compounds that
arise from iterative type II polyketide synthases, considerable interest has developed to gain
access to these microbial secondary metabolites (O’Hagan 1991). The traditional protocol used
to isolate and identify natural products from bacteria is to first culture an individual bacterium
from the environment, extract bacterial cultures using organic solvents, and isolate pure
compounds through activity guided fractionation. However, as mentioned earlier, the difficulties
associated with culturing environmental bacteria prevent traditional culture-dependent methods
from being applied to a significant fraction of the bacterial species found in nature. On the other
hand, culture-independent metagenomic strategies involve direct cloning of DNA from
environmental samples, which contain the genes encoding for small molecule, bypassing the
need for isolation and culture of new bacterial species. PCR based studies as well as shotgunsequencing efforts indicate that eDNA samples are rich in unique minimal PKS genes (Seow et
al. 1997, Wawrik et al. 2007, Pang et al. 2008).

These types of culture-independent techniques are the basis of the work described in this chapter.
There have been multiple reports in the literature describing the identification of type II PKS
genes from eDNA samples. King, Brady et al. expressed a pathway encoding the biosynthesis of
a type II polyketide and characterized a new molecule, erdacin (King et al. 2009) with previously
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unknown pentacyclic skeleton, lending credence to the idea that metagenomics could be
successfully implemented to tap into the chemical diversity of type II PKS-derived molecules
from uncultured bacteria. Since this report, several other reports have been published detailing
the discovery of additional novel type II PKS-derived compounds, such as bioactive pentangular
polyphenols, calixanthomycin A, arenimycins C-D, arixanthomycins A-C (Kang and Brady
2014, Kang and Brady 2013), fasamycins (Feng, Kallifidas et al. 2011; Feng, Chakraborty et al.
2012), fluostatin F (Feng, Kim et al. 2010), and MRSA-active antibiotic tetarimycin A
(Kallifidas, Kang et al. 2012) to mention a few. Taken together, all these reports offer a glimpse
of the previously unseen chemistry of the type II PKS derived natural products that metagenomic
screening has the potential to uncover.
Aromatic polyketide synthases (type II PKSs) are a family of multienzyme systems that catalyze
the biosynthesis of a structurally diverse and pharmaceutically important class of natural
products known as aromatic type II polyketides (Hopwood, 1997). Many of these molecules
exhibit anticancer (e.g. doxorubicin), antibacterial (e.g. oxytetracycline), antifungal (e.g.
pradimicin), antiviral (e.g. A-74528) and other related medicinally important activities (O'Hagan,
1991). These molecules are synthesized, in part, by multifunctional polyketide synthases (PKSs),
which catalyze repeated decarboxylative condensations between acyl thioesters (acetyl,
propionyl, malonyl, methylmalonyl, etc.). Type II PKS systems comprise of aggregates of small
polypeptides, each having a single catalytic activity that is used iteratively during the
biosynthesis. All type II PKS gene clusters encode a “minimal PKS” consisting of three
functionally discrete proteins: a ketosynthase (KSα), chain length factor (KSβ), and acyl carrier
protein (ACP). This core of three enzymes is responsible for the construction of the polyketide
backbone through iterative condensation of multiple acyl-CoA units (Figure 19). Additional PKS
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subunits, ketoreductases, cyclases and aromatases determine the folding pattern of the nascent
poly-β-keto intermediate and a set of tailoring enzymes, such as oxygenase, glycosyltransferase,
etc. further functionalize the aromatic polyphenols to create the final polyketide natural products
(Shen 2000, Rawlings 1999, Hertweck 2009)
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Figure 19. Iterative use of the minimal PKS for the assembly of aromatic type II polyketide backbone. Minimal
PKS composed of three proteins: ketosynthase alpha (KSα), ketosynthase beta/chain length factor (KSβ), and acyl
carrier protein, ACP. The minimal PKS is responsible for the iterative condensation of malonyl CoAs into a nascent
polyketide chain that is then cyclized, aromatized, reduced, oxidized, rearranged, and functionalized in pathwayspecific ways to generate structural diversity that is known to arise from type II PKS systems

The cloning and analysis of DNA extracted directly from environmental samples (environmental
DNA, eDNA) provides a means of exploring the biosynthetic capacity of natural bacterial
populations. eDNA libraries are essentially large reservoirs of bacterial genetic diversity from
which new secondary metabolite gene clusters can be systematically recovered and studied. In
this chapter, I describe my efforts to gain access to the chemical diversity of the aromatic natural
products synthesized by bacterial type II polyketide synthases (PKSs) through metagenomic
approaches. Through homology-based screening of a large metagenomic library, I identified, for
the first time, the gene cluster for the biosynthesis of the known Type II PKS derived
angucycline antibiotic seitomycin and related natural products (Abdelfattah et. al. 2003).
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3.2 Results
3.2.1 Screening for Type II PKS pathways
In our attempt to identify novel type II polyketide natural products, a multimillion membered
metagenomic library constructed using sample collected from Texas was screened. The
biosynthetic gene-clusters of these natural products contain, among other genes, a set of three
highly conserved genes, a ketosynthase (KSα), a chain

KSα"

CLF

ACP

length factor (CLF or KSβ) and an acyl carrier protein
(ACP) (Figure 19, 20). For the present work, I used a set
of degenerate primers targeting conserved regions on the
conserved KSα gene to perform homology-based screening

dp:540F

dp:1100R

Figure 20. eDNA derived PKS probes:
Unique KSα genes were used as probes to
recover type II PKS containing clones from
the metagenomic libraries.

of the environmental DNA (eDNA) library. It has been shown previously that KSα genes group
into clades that correlate well with the chain length and initial cyclization pattern of the
polyketide precursor produced by a gene cluster (Wawrik et al. 2005). KSα genes can therefore
be used as bioinformatics markers for predicting both the length of the polyketide chain produced
by a minimal PKS and the initial polyketide cyclization pattern of the polyketide chain. The
primers (dp:540F and dp:1100R, Figure 20) were designed to amplify ~550 bp long DNA
sequence from the Texas (Tx) library (Figure 21). In order to characterize the amplicons, BLAST
search was performed on individual sequences, followed by a ClustalW-based phylogenetic
analysis comparing the eDNA derived KSα sequences to those from functionally characterized or
known type II PKS clusters. It’s been found that type II PKS clusters with KSα gene sharing
>85% identity, tend to encode for molecules with very similar chemical structures (Reddy et al.
2012). Clustering KSα sequences at 85% identity revealed 91 unique sequences from the Tx
library (Figure 22, 23). A summary of the results of the screen is presented in Figure 21.
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Texas Library

(10 7)

Homology
screening
450 hits

Sequence
analysis

91 unique type
II PKS clones

Clone recovery
from library
1 clone (cosTX451)
produced clone-specific
metabolites

Heterologous
expression

30 clones recovered

Figure 2. An overview of Texas library screening results

Figure 21. An overview of TX library screening results.

3.2.2 Recovery, retrofitting and heterologous expression of eDNA-derived Type II PKS pathways
Based on the above analyses, forty clones carrying unique KSα sequences were picked for
recovery. In order to recover the clones from eDNA library, the unique KSα sequences were used
as probes. A second set of specific primers was designed based on the particular amplicon
sequence of that KSα gene obtained during our initial screening. The type II PKS cosmid clones
of interest were then recovered from library using successive rounds of serial dilution and PCR
screening. In total thirty type II PKS gene containing clones were recovered and carried forward
for functional analysis (Figure 21, 22).
Although, the metagenomic libraries are constructed in E. coli, it is not a desirable host for
heterologous expression of small molecules. Instead Streptomyces albus was chosen as the
heterologous host for our expression studies. The predominantly soil dwelling gram-positive
Streptomyces sp. is well known for secondary metabolite production and is the source for about
two-thirds of clinically useful antibiotic natural products (Kieser, Bibb et al. 2000). Streptomyces
sp. has extensive precedent as a successful heterologous host (Pfeifer and Khosla 2001).
Furthermore, nearly all of the identified KSα genes in this work have closest homology with KSα
genes from Streptomyces sp.
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Method: Neighbor Joining; Best Tree; tie breaking = Systematic
Distance: Tamura-Nei; Gamma correction = Off
Gaps distributed proportionally

E.coli fabB
D366-540F.seq
J922-540F.seq
G634-540F.seq
K1020-540F.seq
C273-540F.seq
K1022-540F.seq
L1065-540F.seq
K1030-540F.seq

Figure 22. A ClustalW-based phylogenetic tree of the eDNAderived KSa genes is shown. Thirty clones (underlined) were
selected randomly for recovery. The tree was constructed using
the Neighbor-joining method. E. Coli fabB gene was used as an
outgroup.
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Figure 23. Comparion of the cosTX451 derived KSα
amplicon sequence with those from sequenced PKS gene
clusters that encode known type II PKS derived
secondary metabolites. ClustalW-based phylogenetic tree
was constructed using Neighbor-joining method. Shown
here is an angucycline carbon skeleton.
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Streptomyces albus has proved to be an extremely efficient heterologous host because of its
relatively fast growth rate, ample sporulation and ease of conjugation with E. coli. These factors
helped facilitate both the conjugation of eDNA-derived Type-II PKS gene cluster into S. albus
and the characterization of the molecules these pathways encode for.
Recovered clones from the Tx library containing type II PKS genes were retrofitted so that they
could be conjugated into S. albus for heterologous expression studies. Recovered cosmids were
digested with PsiI, which cuts in the cosmid vector but rarely cuts in eDNA inserts. Each
linearized cosmid was then ligated with the 6.81 kb DraI fragment from pOJ436 (Feng et al.
2011). This fragment contains an origin of transfer (oriT) and elements of the phiC31 attp-attB
integration system needed for integration into diverse Streptomyces sp. (Bierman et al. 1992).
Retrofitted cosmids were transformed into E. coli S17.1 and conjugated into S. albus using
standard Streptomyces conjugation protocols (Practical Streptomyces Genetics by T. Kieser, M.
J. Bibb, M. J. Buttner, K. F. Chater, D. A. Hopwood).

Color production, TLC and HPLC-MS analysis were used to identify clone specific metabolite
production in recombinant Streptomyces harboring PKS pathways. In the present screen, out of
thirty PKS gene clusters from Tx library examined in this study, one clone, cosTX451, conferred
the production of clone specific metabolites to S. albus, based on visual inspection, TLC and
HPLC-MS of crude extracts (Figure 24). A number of clone-specific metabolites were observed
upon HPLC-MS analyses of the fermentation broth extracts derived from S. albus transformed
with cosTX451 (Figure 22). A ClustalW-based phylogenetic analysis using KSα genes from the
eDNA derived clone cosTX451 as well as those from functionally characterized type II gene
clusters indicated that the pathway cosTX451 was likely to produce angucycline (Rohr et al.
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1992) family of type II polyketide natural products (Figure 23). The closest homolog to this KSα
gene is from the hatomarubigin pathway from Streptomyces sp. strain 2238-SVT4 (Hayakawa et
al. 1991).

Figure 24. S. albus transformed with eDNA-derived PKS clone cosTX451 was screened for the production of clone
specific metabolites. a) LC-MS analysis of crude ethyl acetate extract of Streptomyces culture broth showed multiple
clone-specific peaks (red triangles). Clone-specific metabolite 2 was isolated for characterization. A negative control
was carried out using S. albus transformed with empty vector. b) Recombinant S. albus on MS agar plates showed
colored metabolite production for clone cosTX451. Empty vector control did not show strong color phenotype.

3.2.3 Sequencing of PKS containing eDNA-derived clones
In order to reveal the gene sequence and organization, the eDNA insert in cosTX451 clone has
been fully sequenced. From the sequencing results, the polyketide biosynthetic pathway appears
to be only partially captured in this clone. Two overlapping clones, cosTX578 and cosTX2512,
were identified by rescreening the Tx library using primer pairs designed to recognize both the
proximal and distal ends of cosTX451. These clones were successfully recovered and sequenced.
Sequencing data analysis of cosTX578 revealed no relevant biosynthetic genes. Other
overlapping clone, cosTX2512, however contained additional type II PKS biosynthetic genes
that could reconstruct the original pathway. The completed sequencing efforts on cosTX451 and
cosTX2512 revealed ~30 kb biosynthetic gene cluster containing 31 predicted open reading
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frame (ORFs) (Figure 25). These 31 ORFs include the minimal PKS, ketoreductase, cyclase, and
aromatase expected in a type II PKS gene cluster. Additionally, a number of post-PKS enzymes,
regulatory proteins, a transporter and several hypothetical proteins are also encoded for by this
gene cluster. Phylogenetic comparison of the minimal PKS gene sequences revealed they are
most closely related to the angucyclines hatomarubigin (Kawasaki et al. 2010) and jadomycin
(Han et al. 1994) pathways (Figure 23).
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Figure 25. ORF diagram and gene table for TX451/2512 pathway. ORFs were predicted using MetaGeneMark and
predicted ORFs were annotated by Blast search and Pfam domain analysis. MacVector was used for sequence
manipulation.
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3.2.4 Overlapping-clone recovery and transformation-associated recombination (TAR) of eDNAderived Type II PKS pathways
In the present screen, I identified one clone (cosTX451) that conferred the production of clone
specific metabolites to S. albus. A number of clone-specific metabolites were observed upon
HPLC-MS analyses of the fermentation broth extracts derived from S. albus transformed with
cosTX451.
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Figure 26. TAR cloning of two overlapping eDNA clones carrying the type II PKS pathway BAC:TX451/2512. The
TAR reassembled construct was shuttled into S. albus for heterologous expression experiments.

Full sequencing of the eDNA insert in cosTX451 revealed that the biosynthetic pathway is only
partially captured in this cosmid. In order to gain access to the complete pathway, one
overlapping clones, cosTX2512, was identified and recovered by rescreening the Tx library
using primer pairs designed to recognize both the proximal and distal ends of cosTX451 (Figure
26). Sequence analysis of cosTX2512 suggested that this clone captures a large part of the
pathway and the reassembled pathway was likely to produce fully functionalized secondary
metabolites. This sequencing data further corroborated our conclusion that the current type II
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PKS gene-cluster is novel and had not been reported in literature previously. Therefore,
cosTX451 was assembled with the overlapping clone cosTX2512 into a complete pathway
through Transformation Associated Recombination (TAR) in Saccharomyces cerevisiae (Feng,
Kim et al. 2010; Kim et al. 2010) into a larger bacterial artificial chromosome (BAC) clone
(Figure 26). The construct BAC:TX451/2512 was confirmed with sequencing and conjugated
into S. albus for heterologous expression (Figure 26).
3.2.5 Isolation and structural characterization of eDNA encoded natural products: Seitomycin,
Rabelomycin, 8-Methylrabelomycin and 1-Deoxo-1-hydroxy-8-O-methylrabelomycin
To learn more about the molecules encoded by eDNA-derived Type-II PKS gene cluster, the
major clone specific metabolites of the recombinant S. albus BAC:TX451/2512 clone was
isolated and structurally characterized. The secondary metabolite profile obtained from
heterologous expression of the TAR construct (BAC:TX451/2512) was different from what was
observed for cosTX451 alone (Figure 27). Attempts were made to isolate and structurally
characterize metabolites from the truncated cosTX451 pathway. However, only one metabolite
(4) was successfully isolated from this clone. The rest of the compounds appeared to be unstable
and attempts to isolate them were unsuccessful. Efforts were focused on the isolation and
structural elucidation of the clone-specific metabolites produced by the fully assembled pathway.
Cultures of S. albus transformed with BAC:TX451/2512 were grown in R5A media. After
incubating at 30 °C for 10 days, the cultures were extracted with ethyl acetate. This crude extract
was partitioned by reversed phase HPLC to isolate the major metabolites. An extensive 1- and 2D NMR analysis utilizing 1HNMR,

13

CNMR, COSY, HMBC and HMQC were employed to

deduce a potential structure of the metabolites 1-4.
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Figure 27. HPLC analysis of crude ethyl acetate extracts of S. albus harboring BAC:TC451/2512 and
cosTX451clones. The secondary metabolite profile obtained from heterologous expression of the TAR construct
(BAC:TX451/2512) was different from what was observed for cosTX451 alone. Compounds 1-4 were isolated for
further analysis.

Characterization of seitomycin (1)
The 1H NMR spectrum showed the presence of H-bonded OH group at δ 12.3, and two pairs of
aromatic protons at δ 8.0/7.6 (5-H, 6-H) and 7.64/7.4 (9-H, 10-H) that appeared as doublets with
coupling constants 8.0 and 9.4 Hz, respectively. In the aliphatic region, two singlets at 3.9 (8OCH3) and 1.3 (3-CH3) each for three hydrogens indicated the presence of methoxy and methyl
groups. Presence of two AB at 2.8 and 3.0 (4-H) and ABX at 2.0 and 1.8 (2-H) signals, was due
to two methylene groups. A triplet at 5.8 (1-H) suggests the presence of one H attached to an
oxygen-attached carbon and next to the ABX methylene group.
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Figure 28. Structural characterization of Seitomycin (1). a) Chemical structure of Seitomycin with carbon numbering. b)
Table showing chemical shifts and coupling constants in 1H and 13C NMR spectra. c) COSY and HBMC correlations
present in Seitomycin.

The 13C NMR spectrum consisted of 20 signals, of which two are carbonyl groups at δ 192 (C12) and 181.8 (C-7), twelve aromatic and six aliphatic carbons. Two aromatic carbons at 155.9
(C-11) and 154 (C-8) and three aliphatic signals at 68.2 (C-3), 64.7 (C-1) and 57.6 (8-OCH3) are
likely oxygen attached. Given that there are only four aromatic hydrogens, it is rational to say
that the remaining eight aromatic carbons are quaternary, two of which are oxygen attached.
Among the aliphatic carbons, two methyl and two methylene groups are present. Existence of a
methine group carrying a triplet hydrogen at δ 5.8 is highly likely.

In the HMBC spectrum, the first set of ortho-positioned aromatic protons at δ 7.64 and 7.4
coupled with carbon signals at δ 155.9 (C-11) and 119.1 (C-7a), and at δ 154.0 (C-8) and 118.1
(C-11a), respectively. The OH signal at δ 12.3 showed couplings to signals at δ 155.9 (C-11),
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126.8 (C-10) and 118.1 (C-11a), and the methoxy protons correlated with a signal at δ 154.0 (C8). Strong 1H-1H COSY correlations were observed between the protons at δ 7.64 and 7.4. In the
HMQC spectrum, these protons showed connectivity to carbons at 124.6 (C-9) and 126.8 (C-10),
respectively. Methoxy protons are attached to a carbon at δ 57.6. These combined 1H-1H COSY,
HMBC and HMQC correlations allowed to construct a p-methoxy-phenol moiety present in
seitomycin. Similarly, the other pair of aromatic ortho-protons at δ 8.0 and 7.6, respectively,
showed relevant three-bond couplings with signals at δ 181.8 (C-7), 142.2 (C-4a), 131.6 (C-12a)
and at δ 142.6 (C-12b), 135.5 (C-6a) and 45.5 (C-4). In addition to having strong 1H-1H COSY
correlations, these protons at δ 8.0 and 7.6 are connected to carbons at 126.4 and 136.4 as
revealed by HMQC. This and the COSY, HMBC and HMQC correlations of the aliphatic
protons revealed the right half of the molecule. Due to the missing couplings of aliphatic ring
protons with the quinone carbonyls, the position of the methoxy group at C8 or C11 could not be
directly deduced from the HMBC spectrum. The
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C signal of a chelated carbonyl group in a

quinone is, however, usually by about Δδ 10 at deeper field as that of the non-chelated carbonyl.
Since the H6 signal couples in the HMBC spectrum with the non-chelated quinone carbonyl at
181.8 (C7), the methoxy group must be located at C8 and the phenolic OH group therefore at
C11, resulting in structure 1 for seitomycin (Abdelfattah et. al. 2003).

Characterization of rabelomycin (2)
The 1H NMR spectrum showed the presence of two chelated OH groups at δ 11.6 (8-OH) and
12.3 (6-OH), and four aromatic protons: a singlet at δ 71.5 (5-H), two doublets at δ 7.49 (11-H)
and 7.35 (9-H) each with coupling constants 8 Hz, and a triplet at δ 7.8 (10-H) with a coupling
constant of 8 Hz. From the characteristic splitting pattern and the identical coupling constant
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values, it appears that the three protons at δ 7.49, 7.35 and 7.8 are in the same aromatic rings. In
the aliphatic region, a singlet at δ 1.3 (3-CH3) for three hydrogens indicated the presence of a
methyl group. Presence of a pair of AB systems at δ 3.0/3.1 (4-H) and 2.68/2.95 (2-H) were due
to two methylene groups.
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Figure 29. Structural characterization of Rabelomycin (2). a) Chemical structure of Rabelomycin with carbon
numbering. b) Table showing chemical shifts and coupling constants in 1H and 13C NMR spectra. c) COSY and HBMC
correlations present in Rabelomycin.

The

13

C NMR spectrum consisted of 19 signals, of which three are carbonyl groups at δ 195.8

(C-1), 191.0 (C-7) and 183.4 (C-12), twelve aromatic and four aliphatic carbons. Two aromatic
carbons at 162.3 (C-6) and 160.6 (C-8) and one aliphatic carbon at 71.2 (C-3) are likely attached
to oxygen. Given that there are only four aromatic hydrogens, it is likely that remaining eight
aromatic carbons are quaternary, two of which are oxygen attached. Among four aliphatic
carbons, one methyl and two methylene groups are present.
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In the HMBC spectrum, three aromatic protons at δ 7.35, 7.49 and 7.8 made extensive threebond couplings. These protons coupled with carbon signals at δ 116.7 (C-7a) and 121.5 (C-11),
at δ 183.4 (C-12), 116.7 (C-7a) and 123.6 (C-9), and at δ 137.6 (C-10/11a) and 160.6 (C-8),
respectively. The OH signal at δ 11.6 showed couplings to carbon signals at δ 116.7 (C-7a) and
123.6 (C-9). Strong 1H-1H COSY correlations were observed among the three aromatic protons.
In the HMQC spectrum, these protons showed connectivity to carbons at δ 123.6 (C-9), 121.5
(C-11) and 137.5 (C-10/11a), respectively. The combined 1H-1H COSY, HMBC and HMQC
correlations allowed constructing a phenol moiety containing A ring present in rabelomycin.

Similarly, in the HMBC spectrum, the other aromatic proton at δ 7.15 showed relevant threebond couplings with signals at δ 115.5 (C-6a), 152.0 (C-12b) and 43.6 (C-4). The OH signal at δ
12.2 showed correlations with carbons at δ 135.8 (C-5), 115.5 (C-6a) and a two-bond coupling
with carbon 162.3 (C-6). HMQC revealed that proton at δ 7.15 is connected to carbon at δ 135.8
(C-5). Extensive COSY, HMBC and HMQC correlations of the aliphatic protons established the
C and D rings as well as the angular structure of the molecule. Although, there were no
couplings among the protons in the C and D rings with the quinone carbonyls, the positions of
the phenolic groups in A and C rings with respect to the quinone carbonyls C-7 and C-12 were
easily established. Like seitomycin, the

13

C signal of a chelated carbonyl group (C-7) in a

quinone appeared at deeper field by about Δδ 10 compared to that of the non-chelated carbonyl
(C-12). Since the H11 signal couples in the HMBC spectrum with the non-chelated quinone
carbonyl at δ 183.4 (C-12), the phenolic group in ring A must be located at C8. The position of
the phenolic OH group in ring C was placed accordingly, resulting in structure 2 for rabelomycin
(Liu et. al. 1970). This is also in accordance with the reported structure of rabelomycin.
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Characterization of 8-O-methylrabelomycin (3)
Structure of 8-O-methylrabelomycin 3 was determined similarly. The numbers of aromatic and
aliphatic protons as well the coupling patterns are identical to those present in rabelomycin.
Obvious differences were the presence of a methoxy group at δ 3.96 (8-OCH3) and the absence
of phenolic OH at 11.6 with little or no changes in other values in the 1H NMR spectrum.
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Figure 30. Structural characterization of 8-O-methylrabelomycin (3). a) Chemical structure of 8-O-methylrabelomycin
with carbon numbering. b) Table showing chemical shifts and coupling constants in 1H and 13C NMR spectra. c) COSY
and HBMC correlations present in 8-O-methylrabelomycin.

In 13C spectrum, the appearance of a signal at 57.3 (8-OCH3) corroborated with the presence of a
methoxy group. Such observations indicated that the compound is a C8 methoxy derivative of
rabelomycin. Further confirmation came from COSY, HMQC and HMBC correlations. Unlike
rabelomycin, all the HMBC connectivity involving C8 phenolic was absent in the new
compound. However, hydroxyl proton at δ 12.9 (6-OH) correlated well with carbon signals at δ
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119.6 (C-6a), 162.1 (C-6) and 121.6 (C-11), thus confirming the presence of methoxy group at
C8 position. The NMR spectra are identical to those reported for 8-O-methylrabelomycin (Fotso
et. al. 2008).

Characterization of 1-Deoxo-1-hydroxy-8-O-methylrabelomycin (4)
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Figure 31. Structural characterization of 1-Deoxo-1-hydroxy-8-O-methylrabelomycin (4). a) Chemical structure of 1Deoxo-1-hydroxy-8-O-methylrabelomycin with carbon numbering. b) Table showing chemical shifts and coupling
constants in 1H and 13C NMR spectra. c) COSY and HBMC correlations present in 1-Deoxo-1-hydroxy-8-Omethylrabelomycin.

The 1H-NMR spectrum of 4 is very similar to that of 8-O-methylrabelomycin, with the major
difference being the presence in 4 of a broad apparent quartet at δ 5.61 (1-H) and a doublet at δ
4.8 (1-OH). Presence of these protons each with integration one suggested that one of the
carbonyls in 8-O-methylrabelomycin has been reduced. The 1H-1H COSY spectrum showed a
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coupling between the methine at δ 5.6 (1-H) and the doublet of doublet methylene protons at δ
2.13 (2-H) indicating that the C-1 carbonyl has been reduced. The carbon spectrum supported
this conclusion on the basis of only two carbonyl groups at δ 189.0 (C-7) and 187.0 (C-12) in 4
and the presence of an additional methine carbon at δ 64.1. HMQC correlation spectra showed
the connectivity of H-1 to C-1 at δ 64.1. The reduction of the carbonyl at C-1 was further
confirmed by the HMBC correlation of the H-2 protons to C-1 at δ 64.1. Presence of the other
long-range couplings as revealed by HMBC remained identical to those present in 8-Omethylrabelomycin. The spectra are identical to those reported for 1-deoxo-1- hydroxy-8-Omethylrabelomycin (Fotso et. al. 2008).

3.2.6 Proposed biosynthesis of seitomycin
The biosynthesis of the type II PKS derived angucycline compound seitomycin can be
rationalized on the basis of the predicted functions for the genes found within the
BAC:TX451/2512 clone (Figure 25). The intermediate compounds isolated from this pathway,
namely 8-O-methylrabelomycin 3 and 1-deoxo-1-hydroxy-8-O-methylrabelomycin 4 further
support this hypothesis. Type II polyketide synthase (PKS) enzymes utilize a starter unit, most
commonly, acetyl CoA and extender units (9 malonyl CoA) to establish a decaketide backbone
(Figure 28). In our proposed biosynthetic scheme for seitomycin, the C20 angucline backbone (I)
is predicted to be synthesized by enzymes encoded by the minimal PKS genes (6, 7, 8) in the
cluster. The first ring closure is proposed to take place by the action of minimal PKS genes as
well (Khosla 2009). The decaketide intermediate then undergoes further cyclization and
aromatization to establish the tri-cyclic backbone (II) of C20 angucline. A ketoreductase (orf 10),
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cyclase (orf 5) and aromatase (orf 11) in the cluster can be assigned to carry out this
transformation.
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catalyzing an oxidation reaction at C-6 (Kharel et al. 2012).
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Table 3: List of genes not used in biosynthetic hypothesis of seitomycin

The second and third ring closures take place through the action of cyclase (orf 5) and a
decarboxylase (orf 12) to produce the well-known intermediate from angucycline pathways,
UWM6. This intermediate then undergoes spontaneous elimination of one water molecule to
generate intermediate III (Figure 32). This intermediate is then transformed into tetrangomycin,
another well-characterized intermediate from angucycline biosynthesis, by a monooxygenase
(orf 14). This monooxygenase is homologous to LndE enzyme from Landomycin E biosynthetic
gene cluster and is know to oxygenate at C-12 of angucycline backbone (Kharel et al. 2012). In
this biosynthetic proposal, intermediate tetrangomycin is predicted to enter into two distinct
pathways resulting in the formation of differentially hydroxylated angucylines. Hydroxylation at
C-6 of tetrangomycin (orf 15) yields rabelomycin (2), a common shunt product/intermediate
from angucycline pathways. Orf 15 represents an oxygenase-reductase family enzyme that is
homologous with LndM2, which is known to catalyze hydroxylation at C-6 position of
tetrangomycin to produce rabelomycin (Kharel et al. 2012). Methylation of rabelomycin at C-8
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hydroxyl group via an O-methyltransferase (orf 19) leads to 8-O-methyrabelomycin (3), which
through the action of a reductase, most likely orf 17 of our cluster, generates 1-deoxo-1-hydroxy8-O-methylrabelomycin (4). Methylation of tetrangomycin at the C-8 hydroxyl group (orf 19)
followed by the reduction of C-1 carbonyl group (orf 17) and hydroxylation at C-11 by an
oxidoreductase enzyme (orf 16) could lead to the formation seitomycin (1) (Figure 32).

3.3 Discussion
Uncultured soil bacteria is a prolific source of chemical diversity that is yet unexplored. eDNA
libraries constructed using soil samples from different geographical regions could give us access
to the genetic diversity of these uncultured microbes. To discover a broader range of biosynthetic
pathways, an expression independent sequence-based strategy was applied to recover cosmids
containing biosynthetic gene clusters. A number of studies have indicated that eDNA samples
are rich in Type II PKS genes (Pang et al. 2008; Wawrik, Kutliev et al. 2007). I screened a
multimillion membered metagenomic library constructed using sample collected from Texas
using a set of degenerate primers based on the conserved KSα gene from type II PKS cluster as
probe. Preliminary sequence-based screens demonstrated the successful recovery of biosynthetic
cosmids encoding a diverse range of type II polyketides. A phylogenetic analysis was carried out
on the eDNA-derived KSα genes. This analysis confirmed that the Tx eDNA library is rich in
type II PKS biosynthetic pathways. Clustering KSα sequences at 85% identity revealed 91
unique clones. Based on the above analysis, thirty clones carrying unique KSα sequences were
picked at random and were recovered from eDNA library. One clone, cosTX451, was identified
that conferred the production of clone specific metabolites to S. albus. Full sequencing of the
eDNA insert in cosTX451 revealed that the biosynthetic pathway is only partially captured in
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this cosmid. In order to access the complete pathway, one overlapping clone, cosTX2512, was
identified and recovered by rescreening the Tx library. TX451 was assembled with the
overlapping clone cosTX2512 into a complete pathway through Transformation Associated
Recombination (TAR). The secondary metabolite profile obtained from heterologous expression
of the TAR construct (BAC:TX451/2512) was different from what was observed for cosTX451
alone. In total, four natural products were isolated and characterized from this pathway.

Extensive NMR studies revealed that the molecules encoded by this gene cluster indeed
belonged to the angucycline class of type II PKS derived natural products. The angucyclines
represent the largest group of type II PKS-engineered natural products (Rohr and Thiericke
1992). Seitomycin, a Type II PKS derived angucycline antibiotic was isolated as the major
metabolite of this pathway. Although no new metabolites were isolated in this study, using
metagenomic tools, I successfully identified, for the first time, the biosynthetic gene cluster for
the Type II PKS derived angucycline antibiotic Seitomycin. The current study provides further
support to the idea that sequence-based screening of large metagenomic libraries can lead to the
discovery of biosynthetic machinery for new chemistry. These results, together with those of
other small-molecule directed metagenomic studies, suggest that large-scale functional screening
of eDNA derived clones should be a productive strategy for generating structurally previously
uncharacterized gene clusters and chemical entities for use in future drug development efforts.
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3.4 Materials and Methods

3.4.1 General experimental procedures
Streptomyces albus J1074 was used for heterologous expression studies. 1H and 2D NMR data
were obtained on a Bruker Avance-600 spectrometer.

13

C NMR spectra were obtained on a

Bruker Avance-600 spectrometer.

3.4.2 PCR screening of eDNA libraries for KSa genes and clone recovery
Cosmid DNA isolated from the library served as the template to amplify KSα sequences using
previously

described

conditions

and

degenerate

primers

(dp:540F-

GGITGCACSTCIGGIMTSGAC and dp:1100R-CCGATSGCICCSAGIGAGTG) (Wawrik et. al.
2005). Twenty-five microliter PCR reactions contained 50 ng of cosmid DNA, 2.5 µM of each
primer, 2 mM dNTPs, 1Å~ ThermoPol reaction buffer (New England Biolabs), 0.5 unit Taq
DNA polymerase (New England Biolabs), and 5%DMSO. PCR was conducted using the
following touchdown protocol: denaturation (95 °C, 2 min), 8 touchdown cycles [95 °C, 45 s; 65
°C (−1 °C per cycle), 1 min; 72 °C, 2 min], 35 standard cycles (95 °C, 45 s; 58 °C, 1 min; 72 °C,
2 min), and a final extension step (72 °C, 2 min). The PCR amplicons were gel-purified (Qiagen)
and sequenced (Genewiz). A ClustalW-based phylogenetic analysis was carried out on the
eDNA-derived KSα amplicons using MacVector.

Sublibrary pools from which unique KSα genes were amplified were used as the starting point for
the recovery of unique KSα containing eDNA clones. Overnight cultures of sublibraries
containing KSα genes of interest were plated into 96-well microtiter plates at a dilution of 10−6.
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After 18 h at 37 °C, the diluted cultures were screened by whole-cell PCR using KSα specific
primers. PCR positive wells were then plated directly on solid media to yield distinct colonies
that were screened in a second round of whole-cell PCR. The PCR protocol used was as follows:
denaturation (95 °C, 5 min), 36 standard cycles (95 °C, 30 s; 55 °C, 30 s; 72 °C, 40s), and a final
extension step (72 °C, 7 min).

3.4.3 Cosmid retrofitting and integration into Sreptomyces albus
Recovered cosmids were digested with the rare PsiI to ensure that only the pWEB-TNC vector
was cut and not the eDNA insert. Each linearized cosmid was then ligated with the 6.81 kb DraI
fragment from pOJ436. This fragment contains an origin of transfer (oriT), an apramycin
resistance marker, and elements of the phiC31 attp-attB integration system needed for integration
into diverse Streptomyces sp. Retrofitted cosmids were transformed into E. coli S17.1 and
conjugated into Streptomyces using published protocols.

3.4.4 eDNA clone sequencing
PKS containing cosmids recovered from the eDNA libraries were initially sequenced by 454
pyrosequencing (Roche) by Memorial Sloan Kettering Cancer Center Genomics Core
Laboratory. Reads were processed with Newbler (Roche) and Velvet (Zerbino and Birney 2008).
Sequence gaps between assembled contigs generated during 454 sequencing were completed by
primer walking (GENEWIZ). The size and deduced role of the open reading frames of
sequenced cosmids were sequenced by 454-pyrosequencing. ORFs (open reading frames) were
predicted using MetaGeneMark (Zhu et al. 2010), and predicted ORFs were annotated by Blast
search and Pfam domain analysis. MacVector was used for sequence manipulation.
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3.4.5 Transformation-associated recombination (TAR) reassembly of overlapping clones
One overlapping clone for cosTX451 was subsequently identified in the Tx library using clonespecific primers designed to recognize the sequence at one end of cosTX451 (TX451R_FW:
ATCACCTTGTCGGCGTCGTG, TX451R_RV: AGAACCACCTGGAGGTGGTG). Hits were
identified in subpool TX2512. Overlapping eDNA cosmid (designated cosTX2512) was
recovered from these pools using the serial dilution method outlined above. The PCR protocol
used was as follows: denaturation (95, 5 min), 36 standard cycles (95 °C, 30 s; 55 °C, 30 s; 72
°C, 40s), and a final extension step (72 °C, 7 min).
The two overlapping eDNA cosmid clones that are predicted to contain the TX451 gene cluster
(cosTX451 and cosTX2512) were assembled into a single bacterial artificial chromosome (BAC)
clone using transformation-associated recombination (TAR) in yeast and the pTARa BAC
shuttle vector. The pathway-specific TAR capture vector was constructed using InFusion cloning
methodology (Clontech). ~500 bp upstream and downstream homology arms were amplified
from the cos451 and cosTX2512 cosmids, respectively. For cosTX451 and cosTX2512,
homology arms needed for TAR recombination were generated using the following primers:
TX451UPS_FW (5′- CTATCGATCTCGAGGGCTGCGCGACGCGGCCGACC-3′),
TX451UPS_RV (5′- GTGCTGCATGTTAACACGATGGCGATGGGGCCTCC-3′),
TX2512DWS_FW (5′-GTTAACATGCAGCACGGCGACGTGGT- 3′),
TX2512DWS_RV (5′- CCCTGCAGGAGCTCGGGCGCGGCGGAGGTCGACGT-3′)
Primers TX451UPS_FW and TX2512DWS_RV include 15 bp sequences (underlined) that
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overlap with BmtI/SphI linearized pTARa capture vector. Primer TX451UPS_RV was designed
to contain a 15 bp overlap (underlined) with the TX2512DWS_FW primer and an HpaI site
(bold), which was added to facilitate the subsequent linearization of the pathway-specific pTARa
capture vector. Gel-purified amplicons (Qiagen) and BmtI/SphI linearized pTARa were
combined in a standard InFusion cloning reaction (Clontech) to make the pathway-specific
capture vector.

For TAR assembly, 200 ng of DraI-digested cosTX451 and cosTX2512 were mixed with 100 ng
of the HpaI-cut pathway-specific capture vector and then transformed into 200 µL of
Saccharomyces cerevisiae CRY1-2 spheroplasts prepared according to published protocols.
Transformed spheroplasts were mixed with synthetic complete (SC) top agar (1 M sorbitol, 1.92
g/L synthetic complete uracil dropout supplement, 6.7 g/L yeast nitrogen base, 2% glucose, and
2.5% agar) and overlaid onto SC uracil dropout plates. Plates were incubated at 30 °C for 72 h.
DNA was prepared from 12 yeast colonies using a zymolyase lysis protocol (ZYMO
RESEARCH) and screened by PCR with primers designed to recognize sequences from
cosTX451 and cosTX2512. A BAC clone that was “PCR positive” with all the primer sets was
electroporated into E. coli EPI300 (Epicentre). DNA isolated from the resulting E. coli was was
fully sequenced by 454 pyrosequencing and confirmed BAC:TX451/2512 to be faithful
reassemblies of the overlapping cosmid clones.

3.4.6 Heterologous expression and analysis
cosTX451 and BAC:TX451/2512 transformed into E. coli S17.1 and conjugated into S. albus.
Spore stocks of S. albus transformed with the retrofitted cosTX451 or BAC:TX451/2512 clone
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was inoculated in 125 mL baffled flasks containing 50 mL of R5A media (Zhu et al. 2010) (for 1
L: 100 g sucrose, 0.25 g K2SO4, 10.12 g MgCl2•6H2O, 10 g glucose, 0.1 g casamino acids, 5 g
yeast extract, 21 g MOPS, 2 g NaOH, 2 mL R2YE trace elements) and grown at 30 °C (200 rpm)
for 7-10 d. Cultures were then extracted twice with an equal volume of ethyl acetate. The dried
extracts were dissolved in methanol (2-4 mL/L of culture). The sample was then dried,
redissolved in 1-2 mL of methanol. The resulting ethyl acetate extract was compared by LC-MS
to the extract from a similarly grown culture of S. albus transformed with a pTARa empty vector
control (HPLC conditions: 30 min gradient from 5% to 100% aqueous acetonitrile containing
0.1% formic acid, C18, 4.6 mm × 150 mm, 1 mL/min).

3.4.7 Compound extraction and purification of Seitomycin, Rabelomycin, 8-Methylrabelomycin,
1-Deoxo-1-hydroxy-8-O-methylrabelomycin
Compounds 1, 3 and 4 were isolated from 2 L cultures of S. albus harboring BAC:TX451/2512
grown (200 rpm at 30 °C) in 125 mL baffled flasks containing 50 mL of R5A media. 7-10 day
old cultures were extracted with ethyl acetate (1/3, v/v to the culture broth), and the ethyl acetate
was dried in vacuo. Compounds were isolated from the resulting ethyl acetate extract using two
rounds of reversed-phase HPLC (C column, 10 18mm × 250 mm, 3.5 mL/min). The first round
of HPLC (isocratic, 45% acetonitrile containing 0.1% trifluoroacetic acid) yielded three crude
compounds 1 (13.2 min), 3 and 4 (15.7 min), which were repurified by a second round of HPLC
using 65%, 75%, and 77% aqueous methanol with 0.1% trifluoroacetic acid to yield compounds
1 (5 mg L−1), 3 (1.5 mg L−1), and 4 (0.5 mg L−1), respectively. Compound 2 was isolated from 2
L cultures of S. albus harboring cosTX451 grown under the same conditions. . 7-10 day old
cultures were acidifie with 2N HCL (pH 3) and extracted with ethyl acetate (1/3, v/v to the
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culture broth) and the organic layer was dried in vacuo. Compound 2 was isolated from ethyl
acetate extract using two rounds of reversed-phase HPLC (C column, 10 18mm × 250 mm, 3.5
mL/min). The first round of HPLC (isocratic, 50% acetonitrile containing 0.1% trifluoroacetic
acid) was done to get crude compound 2 (12.9 min) which was repurified by a second round of
HPLC using 70 % aqueous methanol with 0.1% trifluoroacetic acid to yield compounds 2 (1.0
mg L−1). Fractions containing desired compounds were dried in vacuo overnight and analyzed by
MS and NMR.
Seitomycin (1): 1H NMR (DMSO-d6, 600 MHz): δ 12.3 (s, 1H), 8.0 (d, J = 7.9 Hz, 1H), 7.64
(d, J = 8.0 Hz, 1H), 7.60 (d, J = 9.4 Hz, 1H), 7.41 (d, J = 9.4 Hz, 1H), 5.80 (t, J = 6.4 Hz, 1H),
4.72 (br s, 1H), 3.91 (s, 3H), 3.04 (d, J = 17.3 Hz, 1H), 2.83 (d, J = 16.9 Hz, 1H), 2.05 (ddd, J =
13.9, 6.7, 1.5 Hz, 1H), 1.82 (dd, J = 13.9, 6.1 Hz, 1H), 1.32 (s, 3H),

Seitomycin (1):

13

C NMR (DMSO-d6, 150 MHz): δ 192.5, 181.7, 155.9, 154.0, 144.2, 142.6,

136.4, 135.5, 131.6, 126.8, 126.4, 124.5, 119.1, 118.1, 68.2, 64.7, 57.6, 45.9, 45.5, 30.9.

Rabelomycin (2): 1H NMR (DMSO-d6, 600 MHz): δ 12.28 (s, 1H), 11.64 (s, 1H), 7.8 (t, J =
8.0 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.15 (s, 1H), 3.47 (br s, 1H), 3.07
(s, 2H), 2.95 (d, J = 15.0 Hz, 1H), 2.68 (d, J = 15.0 Hz, 1H), 1.32 (s, 3H)

Rabelomycin (2): 13C (DMSO-d6, 150 MHz): δ 195.8, 191.0, 183.4, 162.3, 160.6, 152.0, 137.6,
137.5, 135.8, 128.7, 123.6, 121.5, 118.6, 116.7, 115.5, 71.2, 53.2, 43.6, 29.5
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8-O-Methylrabelomycin (3): 1H NMR (DMSO-d6, 600 MHz): δ 12.9 (s, 1H), 7.81 (t, J = 8.0
Hz, 1H), 7.53 (dd, J = 1.5, 8.0 Hz, 1H), 7.46 (dd, J = 1.5, 8.0 Hz, 1H), 6.8 (s, 1H), 4.9 (br s, 1H),
3.96 (s, 3H), 3.03 (s, 1H), 2.91 (d, J = 15.0 Hz, 1H), 2.83 (s, 1H), 2.61 (s, 1H), 1.3 (s, 3H)

8-O-Methylrabelomycin (3):

13

C (DMSO-d6, 150 MHz): δ 195.7, 187.3, 186.2, 162.1, 160.0,

150.3, 140.0, 138.3, 136.3, 123.8, 121.8, 121.6, 119.6, 118.9, 118.7, 71.7, 57.3, 54.1, 44.5, 30.2

1-Deoxo-1-hydroxy-8-O-Methylrabelomycin (4): 1H NMR (DMSO-d6, 600 MHz): δ 13.0 (s,
1H), 7.91 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.10 (s, 1H),
5.61 (m, 1H), 4.8 (br s, 1H), 4.5 (br s, 1H), 4.09 (s, 3H), 2.93 (d, J = 17.0 Hz, 1H), 2.7 (br m,
2H), 2.13 (dd, J = 14.1, 5.5 Hz, 1H), 1.3 (s, 3H)

1-Deoxo-1-hydroxy-8-O-Methylrabelomycin (4): 13C (DMSO-d6, 150 MHz): δ
189.0, 187.0, 161.0, 160.7, 148.4, 137.8, 137.2, 135.0, 132.2, 124.4, 120.2, 120.1, 119.4, 117.2,
68.2, 64.1, 57.4, 45.9, 45.5, 31.0
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Figure 35. 1H-1H COSY spectrum spectrum of Seitomycin (1)
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Figure 36. 1H-13H HMQC spectrum of Seitomycin (1)
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Figure 37. 1H-13H HMBC spectrum of Seitomycin (1)
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Figure 37a. High-resolution mass spectra (HRMS) of Seitomycin (1)
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Figure 39. 1H-1H COSY spectrum spectrum of Rabelomycin (2)
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Figure 41. 13C NMR spectrum of 8-O-Methylrabelomycin (3)

210

110

100

90

80

70

60

50

40

30

20

ppm

81
Figure 42. 1H-13H HMQC spectrum of 8-O-Methylrabelomycin (3)
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Figure 43. 1H-13H HMBC spectrum of 8-O-Methylrabelomycin (3)
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Figure 46. HMQC spectrum of 1-deoxo-1-hydroxy-8-O-methylrabelomycin (4)
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Figure 47. 1H-13H HMBC spectrum of 1-deoxo-1-hydroxy-8-O-methylrabelomycin (4)

CHAPTER 4
Phylogeny-Guided Discovery and Heterologous Expression Studies of Novel
Type II PKS Gene Clusters
4.1 Introduction
Soil microbiome is a vast reservoir of genomic diversity and metabolic pathways that are
intimately associated with novel natural products. Natural product discovery programs have
traditionally relied on random screening of microbial species to identify new chemistry in nature
(Cragg and Newman 2013). However, microorganisms are difficult to culture using laboratorybased methods. It is now common knowledge that direct visualization of microorganisms in a
natural sample by staining and microscopic studies hints toward a population count one to two
orders of magnitude higher than that measured by culturing from that same sample. This has led
to an anomaly: while some microorganisms have been extremely well studied, a great majority
has not been explored at all. The data from 16S ribosomal
RNA (or 16S-rRNA) gene-sequence studies provide
probably the strongest support to the notion that our census

pWEB-based cosmids carrying
30 ~ 40 kb eDNA fragments

of microbial populations is far from comprehensive.
Therefore,

harnessing

the

biosynthetic

capacity

of

environmental microbial species to discover bioactive
chemical compounds is contingent upon overcoming the
“culture bias”.
Recent

advancements

in

various

next-generation

AmpR

col E1
ori

cos
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8.2 kb

NeoR

SV40
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Figure 48. Metagenomic approach to natural
product discovery. Microbial DNA is isolated
from the environment and cloned into E.coli
based vector that can be cultured under
laboratory conditions.

sequencing techniques, bioinformatics analytical tools and DNA cloning methods have caused an
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explosion in the number of studies exploring species diversity of microbial environments (Figure
48). 16S rRNA sequence studies have confirmed that soil is an environment particularly rich in
microbial diversity and hence a promising source of novel chemistry (Hugenholtz, Goebel et al.
1998). Even soil from environments expected to have low diversity, such as landfills or other
contaminated sites, have turned out to be above-average (Nüsslein and Tiedje 1998; Lloyd-Jones
and Lau 1998). Therefore, a systematic sequence-based screening of the soil metagenome should
enable the functional characterization of diverse biosynthetic pathways that lay hidden in nature
(Kallifidas and Brady 2012).
In this chapter, I report the use of a highly conserved biosynthetic gene as a phylogenetic marker
to identify novel gene clusters. This approach can serve to offset new natural product discovery.
I use short conserved biosynthetic gene sequences (sequence tags) amplified from soil microbial
DNA as phylogenetic units to target the discovery of novel aromatic polyphenols (type II
polyketides) from the environment. Aromatic polyketides are a structurally diverse collection of
metabolites having important antimicrobial and anticancer properties (Hertweck, Luzhetskyy et
al. 2007). Even though gene clusters encoding biosynthesis of these metabolites can differ
substantially in gene content, they all contain a conserved set of three proteins: ketosynthase
alpha (KSα) ketosynthase beta/chain length factor (KSβ) and acyl carrier protein (ACP) forming a
polyketide synthase (PKS) unit known as the minimal PKS. Shotgun-sequencing data as well as
PCR-based studies indicate that environmental DNA (eDNA) samples are rich in unique minimal
PKS genes (Kang and Brady, 2014; Feng, Kallifidas et al. 2011; Pang, Tan et al. 2008; Seow et
al. 1997). Significant structural diversity, both in terms of carbon skeleton and functional groups,
coupled with a wide variety of biological activities of this biosynthetic subgroup make aromatic
polyphenols viable targets for the phylogeny-based natural product discovery approach.
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Our efforts to identify novel polyketide natural products began by cataloguing eDNA-derived
type II PKS gene clusters whose ketosynthase beta (KSβ) sequence-tag was phylogenetically
distinct from any known KSβ sequence. In this study, I used polymerase chain reaction (PCR)
amplicon sequences (sequence tags) of KSβ genes from archived soil eDNA libraries to explore
the structural and biosynthetic diversities of aromatic polyphenols. The KSβ gene forms a subunit
of the minimal PKS that is responsible for generating the non-reduced intermediate in aromatic
polyketide biosynthesis (Figure 49). KSβ genes have proven to be robust phylogenetic markers
that represent structural variations in the carbon skeleton of the natural products derived
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Figure 49. Overview of the phylogeny-guided strategy for the discovery of new natural products. eDNA from soil is
used to construct cosmid megalibraries (> 10 000 000 clones), which are arrayed as pools of unique 5000-membered
sublibraries. Aromatic polyketide min-PKS KSβ genes are amplified in PCR reactions with degenerate primers using
DNA from each unique sublibrary within the megalibraries as template. The phylogenetic grouping of eDNA
sequences with KSβ sequences from gene clusters that encode novel natural products is used to guide the recovery of
clones containing gene clusters of interest from specific sublibraries. Heterologous expression of bioinformatically
unique eDNA-derived complete gene clusters can be used to expand the structural diversity of natural products.
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from type II PKS biosynthetic systems (Winter, Sloman et al. 2013; Feng et al. 2011; Sullivan
2005; Nakagawa, Omura et al. 1987). In other words, this single gene can predict the general
class of a type II PKS gene cluster.

The eDNA-derived KSβ amplicons were mapped onto a phylogenetic tree constructed using KSβ
genes from functionally characterized type II PKS clusters. A number of amplicons were found
to fall into the well-defined type II PKS clades, such as anthracycline, tetracycline, angucycline,
pentangular polyphenol etc. (Kang and Brady 2014; Hertweck 2009). Close inspection of the
KSβ gene phylogeny indicated that our

Known compound
Minor modification

soil eDNA libraries contain biosynthetic

Known compound

gene clusters that did not align with any

Minor modification

Novel gene cluster: Novel compound?

known or functionally characterized type
II PKS pathways (Figure 50). These
clusters,

therefore,

could

potentially

Outgroup
Figure 50. Biosynthetic marker phylogeny. Phylogenetic analysis to
identify biosynthetic gene clusters that do not clade with functionally
characterized pathways could lead to natural products with novel
scaffold.

encode for natural products with novel
chemical scaffold and lead to new therapeutics. A selective few of these potentially novel type II
PKS biosynthetic clusters were recovered from the archived libraries and carried forward for
heterologous expression studies.

4.2 Results
4.2.1 KSβ sequence-guided screening of soil eDNA libraries.
To identify novel gene clusters encoding type II PKS, soil eDNA libraries were screened with
degenerate primers targeting the KSβ gene of the min-PKS. KSβ genes clade into groups that
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correlate strongly with the specific aromatic polyketide structural classes that are encoded by the
gene clusters (Kang and Brady 2013; Feng et al. 2011; Ridley, Lee et al. 2008). Based on this
observation, I surmised that it could be possible to systematically screen multimillion-member
eDNA libraries for biosynthetic gene clusters encoding novel members of aromatic polyketide
structural classes using PCR-amplified min-PKS gene fragments as sequence tags. Phylogenetic
trees were constructed with the resulting eDNA KSβ amplicon sequences and sequences from
functionally characterized type II PKS gene clusters available from GenBank database. Through
this analysis, from 78 sequenced type II PKS clones, I identified a group of KSβ sequence tags
from our Anza Borrego Desert (AB) and Arizona (AZ) eDNA libraries that were
phylogenetically distant from KSβ genes from any functionally characterized type II PKS gene
clusters (Figures 51, 52). Gene clusters carrying these “unique” KSβ genes could potentially
encode for novel type II PKS derived metabolites. All these clones were, therefore, recovered
from the archived libraries and fully sequenced. Based on phylogenetic comparison of the KSβ
genes and the gene content of each cluster, I identified three type II PKS pathways that were of
particular interest: AB1215, AB1449 and AZ1237 (Figure 52).
4.2.2 Overlapping clone recovery
Sequencing data for all three cosmid clones, AB1215, AB1449 and AZ1237 indicated that the
above-mentioned biosynthetic clusters were not completely captured in one cosmid clone. This
sequence data was subsequently used to guide the recovery of additional overlapping cosmids in
order to reconstruct the original pathways. Sequencing and bioinformatics annotation of each set
of overlapping cosmid clones revealed biosynthetic gene clusters flanked by collections of genes
predicted to encode primary metabolic enzymes, suggesting that all three gene clusters were
recovered in their entirety on the overlapping cosmids.
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Figure 51. Maximum likelihood tree of KSβ genes from type II PKS gene clusters. we hypothesized that phylogenetic
comparison of eDNA-derived KSβ sequence tags to KSβ genes from functionally characterized gene clusters should enable us
to select structurally distinct metabolites encoded by eDNA-derived gene clusters. AZ and AB denote amplicon sequences
derived from Arizona and California desert soil eDNA libraries, respectively.

Figure 52. A part of the maximum likelihood tree of partial KSβ gene sequences is shown. AZ and AB denote
amplicon sequences derived from Arizona and California desert soil eDNA libraries, respectively. The specific
group of eDNA sequence tags used in this study are highlighted in red boxes.

4.2.3 Gene cluster analysis of complete AB1215, AB1449 and AZ1237 pathways
Biosynthetic highlights of AB1215/183 pathway.
Antibiotics containing sugar moieties are promising, especially regarding their bioactivity and
the engineering of new/ novel analogues through glycodiversification (Kharel et al. 2012).
Sequence analyses of this biosynthetic gene cluster revealed 8 ORFs that could potentially be
involved in the deoxysugar biosynthetic pathways (ORFs 16, 17, 18, 19, 20, 22, 23 and 26)
(Figure 53). The cluster also contains genes for sugar aminotransferase. The cluster, therefore,
encodes for the biosynthesis of type II PKS derived small molecule with aminodeoxy sugars. In
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addition, there is a gene for potential C-glycosylation, which is not very common (Rohr and
Thiericke, 1992; Murenets 1990) and may lead to a structurally novel compound (Figure 53).
Due to the importance of the sugar moiety for bioactivity of aromatic polyphenols
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Figure 53. ORF diagram and gene table for Type II PKS pathway AB1215/183. ORFs were predicted using
MetaGeneMark and predicted ORFs were annotated by Blast search and Pfam domain analysis. MacVector was
used for sequence manipulation.
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and the presence of a combination of post-PKS tailoring enzyme encoding genes such as Cglycosyltransferase the sugar aminotransferase found on clone AB1215/183, I selected to study
this gene cluster using heterologous expression methods.

Biosynthetic highlights of AB1449/647 pathway.
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Figure 54. ORF diagram and gene table for Type II PKS pathway AB1449/647. ORFs were predicted using
MetaGeneMark and predicted ORFs were annotated by Blast search and Pfam domain analysis. MacVector was
used for sequence manipulation.
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Analysis of this biosynthetic gene cluster indicated that there are 4 ORFs that could potentially
be involved in the biosynthesis of deoxysugar (ORFs 9, 10, 13 and 14) (Figure 54). In addition,
there is putative hexose aminotransferase potentially leading to aminodeoxy sugar biosynthesis.
There is a putative C-5 anthrone oxidase (ORF 7) gene in this cluster. This gene is often
responsible for Baeyer-Villiger type oxidative cleavage of a ring system followed by
rearrangements of the carbon scaffold of aromatic polyketides generating novel carbon motif.
Similar genes are also found in certain angucycline gene clusters (GilOI, JadH and UrdM) (Li
and Piel 2002). This cluster encodes for enzymes that can carry out additional post-PKS tailoring
reactions, including the O-methylation, which is promising with regards to structural
diversification (Figure 54). Based on the above analysis, I chose to carry forward this
AB1449/647 type II PKS pathway for heterologous expression studies.

Biosynthetic highlights of AZ2250/1237/2224 pathway.
As mentioned earlier, glycosylation is one of the most important tailoring steps in aromatic
polyketide biosynthesis. In this particular pathway, there are 5 ORFs (ORFs 14, 17, 19, 22 and
36) that could potentially lead to glycosylated natural product (Figure 55). Three of these genes
are actually putative glycosyltransferases. Therefore, this pathway could produce an aromatic
polyphenol with oligosaccharide attachment. Additionally, the presence of a sugar Omethyltransferase can impart further structural diversification (Figure 55). The above features
made this AZ2250/1237/2224 cluster of substantial interest to us, and it was taken forward for
heterologous expression analysis.
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Figure 55. ORF diagram and gene table for Type II PKS pathway AZ2250/1237/2224. ORFs were predicted using
MetaGeneMark and predicted ORFs were annotated by Blast search and Pfam domain analysis. MacVector was
used for sequence manipulation.

4.2.4 TAR cloning for reconstruction type II PKS pathways AB1215, AB1449 and AZ1237
It has been shown that transformation associated recombination (TAR) in Saccharomyces
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cerevisiae could be used to reconstruct large continuous stretches of DNA captured on
overlapping cosmid clones (Kim et al. 2010). To reassemble AB1215 and AB183, AB1449 and
AB647, and AZ2225, AZ1237 and AZ2250 into single DNA fragments that could be used in
heterologous expression studies, cosmids and their corresponding specific yeast capture vector
were co-transformed into S. cerevisiae and allowed to recombine (Figure 56). The bacterial
artificial chromosomes (BACs) constructed in this experiment were completely sequenced and
found to be faithful reassemblies of the overlapping eDNA sequences. These newly assembled
large insert clones were conjugated into S. albus and examined for the production of clone
specific metabolites.

Transformation Associated Recombination

pTARa
capture vector

Tansformation Associated

Figure 56. Transformation Associated Reassembly (TAR)
of overlapping
Recombination
(TAR) eDNA
in Yeast clones in yeast.
Overlapping cosmid clones for the sequence of interest were screened for and recovered from eDNA
Complete pathway
library and assembled into one bacterial artificial chromosome (BAC) clone.
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4.2.5 Heterologous expression of the eDNA-derived gene clusters
In order to examine the AB1215, AB1449 and AZ1237 pathways for production of metabolites
encoded within the clusters, each set of three overlapping eDNA cosmid clones (AB1215,
AB183; AB1449, AB647; AZ2250, AZ1237, AZ2224) was assembled into bacterial artificial
chromosomes (BAC-AB1215/183, BAC-AB1449/647 and BAC-AZ22250/1237/2250) using
pathway specific pTARa (E. coli:yeast:Streptomyces) shuttle capture vectors and transformationassociated recombination (TAR) in yeast ( Kim et al. 2010) (Figure 56). These BAC constructs
were sequenced to ensure correct assembly and subsequently conjugated into Streptomyces albus
by intergenic conjugation and integrated into the Streptomyces genome using the ΦC31
integrase.
m/z$761$

m/z$336$
BAC:AB1215/183$
AB1215$

Figure 57. S. albus transformed with eDNA-derived type II PKS pathway BAC-AB1215/183 was screened for the
production of clone specific metabolites. LC-MS analysis of crude ethyl acetate extract of Streptomyces culture
broth showed one major clone specific peak with m/z 761. No clone specific peaks were observed on LCMS
analysis with S. albus transformed with cosmid AB1215. UV signature is shown for the major clone specific
metabolite.
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For heterologous expression, the resulting strains, S. albus BAC-AB1215/183, S. albus BACAB1449/647 and S. albus BAC-AZ22250/1237/2250, were grown in R5A liquid media for 10
days at 30 °C. LC−MS analysis of ethylacetate extracts derived from these cultures showed the
presence of one major clone-specific peak for BAC-AB1215/183 and BAC-AB1449/647 each
(Figure 57 and 58, respectively). BAC-AZ22250/1237/2250 showed peaks corresponding to
three clone specific metabolites (Figure 59).

BAC:AB1449/647,

AB1449/empty,vector,

Figure 58. S. albus transformed with eDNA-derived type II PKS pathway BAC-AB1449/647 was screened for the
production of clone specific metabolites. LC-MS analysis of crude ethyl acetate extract of Streptomyces culture
broth showed one major clone specific peak. No clone specific peaks were observed on LCMS analysis with S.
albus transformed with cosmid AB1449.
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BAC:AZ1237/2250/2224-

AZ1237/empty-vector-

Figure 59. S. albus transformed with eDNA-derived type II PKS pathway BAC-AZ22250/1237/2250 was screened
for the production of clone specific metabolites. LC-MS analysis of crude ethyl acetate extract of Streptomyces
culture broth showed one major clone specific peak. A control was carried out using S. albus transformed with
cosmid AZ1237 which did not show any clone specific peaks on LCMS analysis.

4.2.6 Complementation of deoxysugar biosynthesis
Extensive sequence analysis of the three type II PKS pathways revealed that AB449/647 and
AZ2250/1237/2224 are missing key genes that are required to initiate sugar biosynthesis. The
AZ2250/1237/2224 pathway has multiple glycosyltransferase genes, but it lacks two critical
genes required for deoxysugar biosynthesis: dNDP-4-keto-6-deoxyglucose 3,5-epimerase and
dNDP-4-ketohexulose reductase, while the AB449/647 pathway is missing the dNDP-D-glucose
synthase gene. Therefore, in all likelihood, pathways AB449/647and AZ2250/1237/2224 are
producing just the aglycone moiety and the final glycosylated product encoded in the pathway.
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These sugar biosynthesis genes appear in the primary metabolic background in some, but not all,
Streptomyces sp. (Rodriguez, Menzella et al. 2009). The early genes required for deoxysugar
biosynthesis were therefore provided in trans (pIJRham). The rhamnose sugar biosynthetic
operon (oleL, oleS, oleE, and oleU) (Rodriguez, Oelkers et al. 2000) from oleandromycin
biosynthesis was cloned under the control of the constitutive ermE* promoter within the
conjugative integrative shuttle expression vector pIJ10257 (Hong, Hutchings et al. 2005). The
pIJRham construct was generated by Dr. Haak-Soo Kang. The pIJRham construct was
subsequently transformed into E. coli S17.1 and conjugated into S.albus/AB1449/647 and
S.albus/AZ2250/1237/22224

to

yield

S.albus/AB1449/647/pIJRham

and

S.albus/AZ2250/1237/22224/pIJRham, respectively.

4.3 Discussion
Soil metagenome is a rich resource for the discovery of novel natural products. In this chapter, I
demonstrate that it is possible to identify collections of natural product gene clusters that encode
novel metabolites using the sequence tag-based metagenomic screening approach. I show that
sequence tags falling in between two well-defined clades associated with different structural
classes can help identify novel biosynthetic gene clusters.

On the basis of the differences in min-PKS gene phylogeny, I shortlisted a collection of type II
PKS gene clusters whose the KSβ genes clade differently from any known existing biosynthetic
clusters of the same family of natural products. The individual proteins that constitute the minPKS (KSα, KSβ, and ACP) are highly conserved across all type II PKS gene clusters. KSβ
phylogenetic tree correlates closely with differences in the core polyketide structure (carbon
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chain length and cyclization pattern) encoded by the gene cluster from which the min-PKS arises
(Khosla 2008). KSβ genes have thus proven to be useful phylogenetic markers for predicting
differences in polyketide core structures encoded by type II PKS gene clusters (Wawrik, Kerkhof
et al. 2005).

I carried out our phylogeny-based bioinformatics analysis on KSβ genes from 78 type II PKS
gene clusters from our archived megalibraries constructed using Anza Borrego Desert soil from
California (AB library) and Arizona (AZ library). Our phylogenetic analysis led to the
identification of three unique eDNA encoded biosynthetic pathways, AB1215, AB1449 and
AZ1237, containing Type II PKS gene clusters that do not clade with any known or functionally
characterized pathways. They could therefore encode for and produce molecules with novel
chemical scaffolds. These cosmid-based clones were fully sequenced and analysis of this
sequencing data indicated that these gene clusters were only partially captured. Incomplete
biosynthetic pathways either remain silent during heterologous expression studies, or they
produce intermediate compounds or shunt products from the pathway. It was therefore essential
that I recover each pathway in its entirety. It’s been shown that an eDNA library of 10 to 15
million clones is likely to contain collections of clones encompassing complete PKS gene
clusters and permit the recovery of overlapping clones from biosynthetic gene clusters found in
the genomes of uncultured bacteria (Kim et al. 2010). I then identified, from the same archived
libraries (consisting of ~107 clones) where these above mentioned pathways were originally
found, multiple overlapping gene clusters and reconstructed these gene clusters on bacterial
artificial chromosome (BAC) clones using Transformation Associated Recombination (TAR) in
yeast (Kim et al. 2010).
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Type II PKS pathway AB1215 and AB1449 were recovered on two overlapping cosmids,
AB1215, AB183 and AB1449, AB647, respectively. AZ1237 was fully captured on three
different cosmids, AZ2250, AZ1237, AZ2224. All the overlapping fragments were sequenced
and the open reading frames (ORFs) of each pathway were assessed using bioinformatics tools.
This analysis confirmed that these clusters were quite unique in their gene content. All three
pathways encode for deoxysugar biosynthesis, which make them promising, both from structural
and bioactivity perspective. AB1215/183 also contain genes for sugar aminotransferase and Cglycosylation, making it an interesting pathway to pursue. AB1449/647 again contains
aminodeoxysugar biosynthesis genes. In addition, there is a putative C-5 anthrone oxidase gene
in this cluster which can effect oxidative rearrangements and lead to a unique carbon skeleton.
Pathway AZ2250/1237/2224 encodes for multiple glycosyltransferases, which can potentially
lead to a unique aromatic polyphenol natural product with oligosaccharide side chain.

Based on both our phylogenetic analysis and ORF predictions, these three pathways were
reassembled into large insert BAC clones using TAR cloning in yeast and subsequently
examined for clone specific metabolite production in heterologous expression host, S. albus.
BAC-AB1215/183 and BAC-AB1449/647 each conferred the production of one clone-specific
metabolite in Streptomyses, whereas three clone specific metabolites were identified from
heterologous expression of BAC-AZ22250/1237/2250 pathway. Characterization of these
metabolites would lead to further information regarding the biosynthetic potential of these gene
clusters.

Close inspection of the three type II PKS pathways indicated that pathways AB449/647 and
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AZ2250/1237/2224 are missing key genes that are required to initiate the deoxysugar
biosynthesis. Therefore, it is likely that pathways AB1449/647 and AZ2250/1237/2224 are
producing just the aglycone moiety and not the final glycosylated product encoded in the
pathway. The critical sugar biosynthesis genes were then provided in trans using pIJRham that
contains the rhamnose sugar biosynthetic operon. Systematic comparative analysis of the
metabolites produced by S. albus exconjugants harboring the BAC clones with and without the
pIJRham construct should lead to definitive answers. Work is underway to better understand the
metabolites produced by these pathways.

The work presented in this chapter demonstrates that one can rapidly access untapped chemical
diversity of highly complex environmental microbiomes using single gene sequence tags. This
methodology is scalable using high throughput sequencing technology and large eDNA libraries.
The current study strengthens the idea that sequence-based eDNA mining approaches like those
used in here can overcome the traditional culture-based natural product discovery paradigm.
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4.4 Materials and Methods
4.4.1 Bioinformatic analysis of KSβ sequence tags
PCR amplicons were gel purified (Qiagen) and Sanger-sequenced (Genewiz). Approximately
600bp of KSβ gene fragments from each amplicon were aligned using ClustalW. Phylogenetic
analysis and pairwise distant calculations were performed using MEGA5.1 (Tamura, Peterson et
al. 2011). All PCR was performed using BioRad Tetrad thermocycler.

4.4.2 Clone recovery and bioinformatics analysis
eDNA clone AB1215, AB1449 and AZ1237 were recovered from the AB (Anza Borrego) and
AZ eDNA libraries by serial dilution of the 5,000-member sub-pool from which the amplicons
were originally amplified. For this, an overnight culture of each sub-pool was inoculated into 96well microtiter plates at a dilution of 10−6. After 18 h of shaking at 37 °C, the diluted cultures
were

screened

by

whole-cell

PCR

using

the

KSβ

screening

primers

(dp:KS-

TTCGGSGGITTCCAGWSIGCSATG and dp:ACP-TCSAKSAGSGCSAISGASTCGTAICC)
(Seow et al. 1997) and touchdown PCR protocol. PCR positive wells were plated onto solid
media (LB agar) to yield distinct colonies that were screened individually in a second round of
whole-cell PCR that was conducted using the following touchdown protocol: denaturation (95
°C, 2 min), 8 touchdown cycles [95 °C, 45 s; 65 °C (−1 °C per cycle), 1 min; 72 °C, 1 min], 35
standard cycles (95 °C, 45 s; 58 °C, 1 min; 72 °C, 1 min) and a final extension step (72 °C, 2
min). Each 25 µL PCR reaction contained 50 ng of cosmid DNA, 2.5 µM of each primer, 2 mM
dNTPs, 1X ThermoPol reaction buffer (New England Biolab), 0.5 units Taq DNA polymerase
and 5% DMSO.
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4.4.3 Cosmid retrofitting and integration into Streptomyces albus
Recovered cosmids were digested with the rare PsiI to ensure that only the pWEB-TNC vector
was cut and not the eDNA insert. Each linearized cosmid was then ligated with the 6.81 kb DraI
fragment from pOJ436. This fragment contains an origin of transfer (oriT), an apramycin
resistance marker, and elements of the phiC31 attp-attB integration system needed for integration
into diverse Streptomyces sp. Retrofitted cosmids were transformed into E. coli S17.1 and
conjugated into Streptomyces using published protocols (Feng, Khallifidas et al. 2011).

4.4.4 Overlapping clone recovery and bioinformatic analysis
Anza Borrego (California) and AZ (Arizona) desert soil eDNA libraries were screened for
overlapping clones for AB1215, AB1449 and AZ1237. These were subsequently identified from
the corresponding library using clone-specific primers designed to recognize the sequence at one
or both ends of the original pathways. The PCR protocol used was as follows: denaturation (95
°C, 5 min), 36 standard cycles (95 °C, 30 s; 55 °C, 30 s; 72 °C, 40s), and a final extension step
(72 °C, 7 min). Overlapping eDNA cosmids were recovered from these pools using the serial
dilution method outlined above. The following primer sets were used:
AB1215 gene cluster
One overlapping clone for AB1215 pathway was identified in the AB library 183 sub-pool using
the following clone-specific primers designed to recognize the sequence at one end of
cosAB1215.
AB183_FW: GGTCGGTTCTGGTGTTGG
AB183_REV: CATGTAGTGGCGGTGGTTC
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AB1449 gene cluster
One overlapping clone for AB1449 pathway was identified in the AB library 647 sub-pool using
the following clone-specific primers designed to recognize the sequence at one end of
cosAB1449.
AB647_FW: GATCAACGAGGCGAACATCG
AB647_REV: TACTGCGGCACCTTCCAGAA

AZ1237 gene cluster
Two overlapping clones for AZ1237 pathway was identified in the AZ library subpools 2224 and
2250 using the following clone-specific primers designed to recognize the sequence at both end
of cosAZ1237.
AZ2224_FW: TCTGCGGGCATGGATGTTAA
AZ2224_REV: GCTTGGCCCATCGAACTCAT

AZ2250_FW: CAGCTTCTCCTCCTCGAGTT
AZ2250_REV: GGACCACTGGAGGTGTTCAA

All cosmids were sequenced by 454-pyrosequencing. ORFs (open reading frames) were
predicted using MetaGeneMark (Zhu, Lomsadze, and Borodovsky 2010) and predicted ORFs
were annotated by Blast search and Pfam domain analysis.
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4.4.5 eDNA clone sequencing
PKS containing cosmids recovered from the eDNA libraries were initially sequenced by 454
pyrosequencing (Roche) at the Memorial Sloan Kettering Cancer Center Genomics Core
Laboratory. All overlapping cosmids and TAR constructs were sequenced using IonTorrent
Personal Genome Machine (PGM). The size and deduced role of the open reading frames
(ORFs) were predicted using MetaGeneMark (Zhu et al. 2010), and predicted ORFs were
annotated by Blast search and Pfam domain analysis. MacVector was used for sequence
manipulation.

4.4.6 Transformation-associated recombination (TAR) reassembly of three overlapping eDNA
clones
Pathway-specific capture vector construction.

The overlapping eDNA cosmid clones were assembled into a single bacterial artificial
chromosome (BAC) clone using transformation-associated recombination (TAR) in yeast and the
pTARa BAC shuttle vector. The pathway-specific TAR capture vector was constructed using
InFusion cloning methodology (Clontech). ~500 bp upstream and downstream homology arms
were amplified from each cosmid. The homology arms needed for TAR recombination were
generated using the following primers:

AB1215 gene cluster (AB1215 and AB189)
AB1215UPS_FW (5′- CTATCGATCTCGAGGGTGGTGGACATCGACCTGAT-3′),
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AB1215UPS_RV (5′- ATGACCGATGTTAACCGTTAATTTCCTCGCACCGG-3′),
AB183DWS_FW (5′-GTTAACATCGGTCATCGGTCGAATGC- 3′),
AB183DWS_RV (5′- CCCTGCAGGAGCTCGATTTCCAGGCTCAGCTCGTC-3′)
AB1449 gene cluster (AB1449 and AB647)
AB1449UPS_FW (5′- CTATCGATCTCGAGGTTGGAAACCAGCCGGATGAC-3′),
AB1449UPS_RV (5′- GACCCGGATGTTAACCGTCCCTCAAGCCGTTCTAA-3′),
AB647DWS_FW (5′-GTTAACATCCGGGTCAACTCCTCGAT- 3′),
AB647DWS_RV (5′- CCCTGCAGGAGCTCGCATCTGTTACGCCAGCCAGA-3′)
AZ1237 gene cluster (AZ2250, AZ1237 and AZ2224)
AZ2250UPS_FW (5′- CTATCGATCTCGAGGGCTGCGGCAATGAACATGAT-3′),
AZ2250UPS_RV (5′- CAGTCCTCTGTTAACGCCTGGACCAACAACACCAT-3′),
AZ2224DWS_FW (5′-GTTAACAGAGGACTGTTCGTGCTGAC- 3′),
AZ2224DWS_RV (5′- CCCTGCAGGAGCTCGATGGACAGTTCGGTGGTGTC-3′)

TAR cloning and pathway assembly
TAR primers include 15 bp sequences (underlined) that overlap with BmtI/SphI linearized
pTARa capture vector. Primer ending with UPS_RV was designed to contain a 15 bp overlap
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(underlined) with the primer ending with DWS_FW primer and an HpaI site (bold), which was
added to facilitate the subsequent linearization of the pathway-specific pTARa capture vector.
Gel-purified amplicons (Qiagen) and BmtI/SphI linearized pTARa were combined in a standard
InFusion cloning reaction (Clontech) to make the pathway-specific capture vector.

For TAR assembly, 200 ng of DraI-digested cosmids were mixed with 100 ng of the HpaI-cut
pathway-specific capture vector and then transformed into 200 µL of Saccharomyces cerevisiae
CRY1-2 spheroplasts prepared according to published protocols (Feng, Khallifidas et al. 2011).
Transformed spheroplasts were mixed with synthetic complete (SC) top agar (1 M sorbitol, 1.92
g/L synthetic complete uracil dropout supplement, 6.7 g/L yeast nitrogen base, 2% glucose, and
2.5% agar) and overlaid onto SC uracil dropout plates. Plates were incubated at 30 °C for 72 h.
DNA was prepared from 12 yeast colonies using a zymolyase lysis protocol (ZYMO
RESEARCH) and screened by PCR with primers designed to recognize sequences from
individual cosmids. A BAC clone that was “PCR positive” with all the primer sets was
electroporated into E. coli EPI300 (Epicentre). DNA isolated from the resulting E. coli was fully
sequenced by IonTorrent Personal Genome Machine (PGM) and confirmed to be faithful
reassemblies of the overlapping cosmid clones.

4.4.7 Heterologous expression and analysis
The cosmid clones (AB1215, AB1449 and AZ1237) as well as the BAC constructs (BACAB1215/183, BAC-AB1449/647 and BAC-AZ2250/1237/2224) were transformed into E. coli
S17.1 and conjugated into Streptomyces albus. Spore stocks of S. albus transformed with the
cosmid or BAC clone was inoculated in 125 mL baffled flasks containing 50 mL of R5A media
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(Zhu et al. 2010) (for 1 L: 100 g sucrose, 0.25 g K2SO4, 10.12 g MgCl2•6H2O, 10 g glucose,
0.1 g casamino acids, 5 g yeast extract, 21 g MOPS, 2 g NaOH, 2 mL R2YE trace elements) and
grown at 30 °C (200 rpm) for 7-10 d. Cultures were then extracted twice with an equal volume of
ethyl acetate. The dried extracts were dissolved in methanol (2-4 mL/L of culture). The sample
was then dried, redissolved in 1-2 mL of methanol. The resulting ethyl acetate extract was
compared by LC-MS to the extract from a similarly grown culture of S. albus transformed with a
pTARa empty vector control (HPLC conditions: 30 min gradient from 5% to 100% aqueous
acetonitrile containing 0.1% formic acid, C18, 4.6 mm × 150 mm, 1 mL/min).
4.4.8 Cloning of the rhamnose biosynthetic genes
pIJRham expression vector containing the rhamnose biosynthetic operon (oleL: dNDP-4-keto-6deoxyglucose 3,5-epimerase, oleS: dNDP-D-glucose synthase, oleE: dNDP-glucose 4,6dehydratase and oleU: dNDP-4-ketohexulose reductase) was transformed into E. coli S17.1 and
then shuttled into S. albus/BAC-AB1215/183, S. albus/BAC-AB1449/647 and S. albus/BACAZ22250/1237/2224 by intergenic conjugation. This expression vector utilizes an orthogonal
phage integration system (ΦBT1) and resistance gene (hygromycin) to those present on the BAC
clones thereby allowing the co-integration of both the biosynthetic gene cluster and the rhamnose
biosynthetic operon into distinct chromosomal sites in S. albus to generate S. albus/BACAB1215/183/pIJRham,

S.

albus/BAC-AB1449/647/pIJRham

AZ22250/1237/2224/pIJRham.
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and

S.

albus/BAC-

CHAPTER 5
Future Directions

5.1 Better bioinformatics
Considering the recent explosion in the number of studies taking advantage of next-generation
sequencing to explore metagenomic or taxonomic diversity of environmental microbiome, we
need better tools to best interpret the data. As of now, interpretation of sequencing data mostly
relies on sequence similarity, on the premise that near identical or similar DNA sequences
translate to identical or similar protein function. Although this general paradigm is valid, as
many studies have demonstrated, our current knowledge and annotations of protein-coding genes
is less than comprehensive. A large number of genes in newly sequenced microorganisms cannot
even be identified or annotated (Roberts, 2004). This impedes our ability to use metagenomics to
study microbial genome diversity as well as functional analysis thereof. Although efforts are
being made to improve the coverage of known genome-derived proteins, we need new
technology to link experimental data to large families of similar proteins. The bias in the genome
and protein databases is one major hindrance to the use of existing annotations. For example, a
large proportion of organisms being sequenced come from the medical community.

Another major concern is that different annotation pipelines potentially produce different results.
Simple processes like comparative genomics routinely require re-analysis of all data involved in
the comparison (Dinsdale et al., 2008). Attempts to create a simple exchange language for
microbial genome analysis have not been successful. With large volumes of data, re-analysis is
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not feasible because data analysis cost will exceed the sequencing cost. Metagenomic analysis
databases need to expand and be better curated to have a sustained annotation infrastructure.

5.2 Large insert metagenomic libraries
A major hurdle to natural product discovery through metagenomics is the recovery of complete
biosynthetic gene clusters from the environment. Natural product biosynthetic gene clusters can
vary in size from a few kilobases to more than 100 kilobases. We have successfully gained
access to some of the natural products encoded in the genomes of uncultured bacteria using
metagenomic techniques. However, the inability to construct very large eDNA libraries with
inserts big enough to capture large biosynthetic pathways on individual clones, has been limiting.
If individual clones could capture >100 kilobases of contiguous eDNA, we would have much
better chance of finding novel chemistry in nature. An obvious solution to this issue is to
construct libraries with larger insert clones that can be used to capture large natural product gene
clusters. It’s now routine to construct of 30–40 kb insert cosmid libraries from environmental
DNA samples. However, making libraries of large insert clones has been challenging. Bacterial
artificial chromosomes or BACs have been used to construct large insert DNA libraries.
However, BAC-based metagenomic libraries are generally two to three orders of magnitude
smaller than those constructed using cosmid-based cloning strategies (Liles, Williamson et al.
2008). It was therefore assumed that the overall coverage had to be compromised in order to
have larger contiguous fragments of DNA. However, advancements in BAC cloning have led to
the construction of libraries containing more than one million clones (Magbanua, Ozkan et al.
2011). Advent of such technology will inevitably revolutionize the field of metagenomics as a
natural product discovery platform.
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5.3 Activation of silent biosynthetic gene clusters
The ongoing exponential growth of genome sequencing data has led to the discovery of many
natural product biosynthesis pathways for which no actual molecule has been characterized. The
biosynthesis of natural products is highly regulated and these clusters often remain silent under
laboratory conditions (Jensen, Chavarria et al. 2014). The regulation is conducted through
dozens of pleiotropic regulatory genes and pathway-specific regulators (Bibb and Hesketh 2009).
They form a complex network in response to a variety of physiological and environmental cues.
The conditions under which a given gene cluster is naturally expressed are largely unknown. A
number of technologies based on genetic engineering are available to induce silent genes. Most
of the successful approaches have been based on generation of gene “knock outs”, promoter
exchange, overexpression of transcription factors or other pleiotropic regulators (Kallifidas and
Brady 2012; Scherlach and Hertweck 2009). Using engineered nucleases is another important
new approach to regulate gene expression in prokaryotes through transcriptional control.
Clustered, regularly interspaced, short palindromic repeat (CRISPR) technology is pioneering
this approach in combination with RNA-guided nucleases, such as Cas9, to edit an organism’s
genome with customizable specificities. Genome editing mediated by CRISPR-Cas9 systems has
been successfully exploited to achieve programmable transcription activation and repression of
bacterial gene expression (Bikard, Jiang et al. 2013). In a recent report from Brady lab, yeast
homologous recombination have been successfully used to exchange all native promoters in
silent gene clusters with constitutively active promoters (Montiel, Kang et al. 2015) which led to
the induction of an otherwise silent pathway. Strategies based on epigenetics has opened new
avenues for the elucidation of the regulation of secondary metabolite formation and will certainly
continue to play a significant role for the elucidation of cryptic natural products (Brakhage
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2013). Then there are simulation strategies that attempt to recreate natural habitat by cocultivation of microorganisms from the same ecosystem (Bertrand, Bohni et al. 2014). Although
a number of such strategies are being explored to activate silent gene clusters, we are in need of a
robust technology that will allow detailed studies across multiple different types of biosynthetic
gene clusters and provide access to the chemistry encoded therein.
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